Published in final edited form as:

J Med Chem. 2011 February 10; 54(3): 765–781. doi:10.1021/jm1008715.

Discovery, Synthesis and Biological Evaluation of a Novel Group of Selective Inhibitors of Filoviral Entry

Maria V. Yermolina^{†,‡}, Jizhen Wang^{†,‡}, Michael Caffrey[§], Lijun L. Rong[‡], and Duncan J. Wardrop^{*,†}

[†]Department of Chemistry, University of Illinois, 845 West Taylor Street, Chicago, Illinois 60607

[‡]Department of Microbiology & Immunology, University of Illinois at Chicago, 835 South Wolcott, Chicago, Illinois 60612

[§]Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, 900 S Ashland, Chicago, IL 60607

Abstract

Herein, we report the development of an anti-filoviral screening system, based on a pseudotyping strategy, and its application in the discovery of a novel group of small molecules that selectively inhibit the Ebola and Marburg glycoprotein (GP)-mediated infection of human cells. Using Ebola Zaire GP-pseudotyped HIV particles bearing a luciferase reporter gene and 293T cells, a library of 237 small molecules was screened for inhibition of GP-mediated viral entry. From this assay, lead compound **8a** was identified as a selective inhibitor of filoviral entry with an IC₅₀ of 30 μM. In order to analyze functional group requirements for efficacy, a structure-activity relationship analysis of this 3,5-disubstituted isoxazole was then conducted with 56 isoxazole and triazole derivatives prepared using “click” chemistry. This study revealed that while the isoxazole ring can be replaced by a triazole system, the 5-(diethylamino)acetamido substituent found in **8a** is required for inhibition of viral-cell entry. Variation of the 3-aryl substituent provided a number of more potent anti-viral agents with IC₅₀ values ranging to 2.5 μM. Lead compound **8a** and three of its derivatives were also found to block the Marburg glycoprotein (GP)-mediated infection of human cells.

Keywords

Ebola; Marburg; entry inhibitor; click chemistry; antiviral agents; bioterrorism; drug development; filovirus

Introduction

The Ebola and Marburg viruses are enveloped, non-segmented, single-stranded RNA viruses and among the most dangerous pathogens known. They abruptly emerge in Central Africa, spread rapidly, cause epidemics of severe hemorrhagic fever with unmatched mortality rates (up to 90%) and, as such, are classified as biosafety level 4 agents.¹ Since their respective identification in 1967 and 1976, there have been more than 2300 reported cases of Ebola and

^{*}To whom correspondence should be addressed: Phone: 312-355-1035. Fax: 312-996-0431. wardropd@uic.edu. .

[‡]These authors contributed equally to this work.

Supporting Information Available: A schematic representation of the production of Ebola GP-pseudotyped HIV viruses and the transduction mediated by them. ¹H and ¹³C NMR spectra for all new compounds described in the work. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Marburg hemorrhagic fever, one-half of which occurred in the last decade. In addition to its effect on humans, there is compelling evidence that Ebola has simultaneously contributed to the catastrophic decline in the western gorilla population in regions of west-central Africa.²

Despite recent progress towards the production of vaccines³ and neutralizing monoclonal antibodies⁴ for the prophylaxis of the Ebola and Marburg viruses, it may never be entirely practical, or for that matter, desirable, to inoculate large portions of the population against these emerging pathogens. For that reason and given the growing concern that members of the family *Filoviridae* might be employed as agents of bioterrorism,⁵ the concurrent identification and development of antiviral agents that can substantially mitigate the effects of filoviral infections is a public health priority.

Notwithstanding an increasing understanding of the pathology of filoviruses, only a limited number of low-molecular-weight inhibitors of these systems have been discovered, to date.⁶ Existing anti-filoviral agents can be characterized by three general modes of action, including a) impairment of viral mRNA methylation; b) stimulation of innate antiviral mechanisms; and c) prevention of virion entry and/or fusion (Figure 1). With regards to the former group, the carbocyclic adenosine analog 3-deazaadenosine (C-c3Ado, **1**)⁷ blocks the cellular enzyme *S*-adenosylhomocysteine hydrolase (SAH) and inhibits the replication of Ebola Zaire *in vitro*, with an IC₅₀ of 30 μ M.⁸ The activity of this antiviral agent has been attributed to diminished methylation of the 5' cap of viral mRNA by (guanine-7-)-methyltransferase, which impairs the translation of viral transcripts.⁹ Administration of **1** to Ebola-infected mice has also been found to dramatically increase production of IFN- α ,¹⁰ which may serve to counteract the virus's suppression of the innate antiviral response. Unfortunately, compound **1** failed to promote IFN- α production in Ebola-infected monkeys.¹¹ Glycyrrhizinic acid (**2**), a triterpene glycoside present in licorice extract, has been found to inhibit the replication of a number of viruses, including Marburg and Ebola.¹² In this case, large doses of compound **2** partially protected Ebola-infected mice and slowed the onset of infection, but ultimately did not prevent death. Although the precise mode of action has yet to be delineated, there is evidence that **2** may induce IFN- α production as well as inhibit membrane penetration and uncoating of the Ebola virus.¹³

Since EBOV enters target cells by an endocytic pathway,¹⁴ agents that disrupt the efficient trafficking of internalized vesicles, via the various components of the cytoskeleton, hold the potential to abrogate its entry and fusion into cells. Indeed, latrunculin (**3**) and colchicine (**4**), which respectively impairs the formation of microfilaments and microtubules, have been shown to prevent the infection of HeLa cells by Ebola virus GP pseudotypes.¹⁵ Given the importance of low endosome pH during the GP-mediated internalization process, lysosomotropic agents²⁷¹⁶ which prevent vesicle and endosome acidification are also potential antifiloviral agents. Indeed, HeLa cells pretreated with the bafilomycin A1 (**5**), an inhibitor of vacuolar ATPase, are resistant to infection by pseudotyped HIV-1 virions.¹⁵ This general observation has been touted as evidence for the existence of an acid-dependant, post-endocytic conformational change in the virus GP,¹⁷ or as has more recently been suggested, that one or more acid-dependant endosomal proteases are involved in the infection process. In this regard, the groups of Cunningham¹⁸ and White¹⁹ have independently demonstrated that the proteases, cathepsin B (CatB) and cathepsin L (CatL) play a key role in viral entry by mediating proteolysis of the EBOV GP. Selective inhibitors of the former enzyme, including CA-074Me (**6**), have been shown to reduce the infectivity of VSV pseudotypes bearing Ebola virus GP. The importance of CatB in the EBOV infection process is further underlined by Goldsmith's observation¹⁷ that pretreatment of HeLa cells with the CatB *N*-glycosylation inhibitor tunicamycin (**7**)²⁰ serves to diminish infection by Ebola GP-pseudotyped HIV virions. Unfortunately, given the demonstrated hypersensitivity of Ebola GP to digestion by other proteases,²¹ such as thermolysin, the clinical prospects

for antiviral agents that solely target CatB and CatL are not encouraging. More recently, Davey and co-workers have successfully employed siRNA screening to identify cellular gene products, namely calmodulin kinase 2 and phosphatidylinositol-3-kinase, which play critical roles in the infection of cells by the Zaire Ebola virus.²² Having identified these potential targets for therapeutic intervention, it was found that KN-9323 and LY294002,²⁴ known inhibitors of these respective enzymes, effectively block infection by both Ebola GP-pseudotyped HIV particles and live Ebola viruses.

While the inherent difficulties associated with handling filoviruses have undoubtedly contributed to the slow pace of the development of potential therapeutic agents, the advent of replication-competent pseudotyped or chimeric viruses,²⁵ which utilize the replication machinery of vesicular stomatitis viruses (VSV),²⁶ murine leukemia viruses (MLV),²⁷ or human immunodeficiency viruses (HIV),²⁸ but package the Ebola and Marburg membrane glycoproteins (GP) on the virion surface offer an opportunity to screen libraries of small molecules for antiviral properties under low level containment (biosafety level 2).²⁹ Furthermore, since this is a cell-based assay, it has an inherent bias against hit compounds, which display cytotoxic properties. While it must be understood that pseudotyped viruses are not the same as wild type filoviruses, the functionality of the surface Ebola glycoprotein in these systems has been shown to closely mimic the native virus with regards to tropism, cell binding and penetration.²⁷ Given the proximal nature of viral fusion and entry during the life cycle of filoviruses, it is this process which appears to merit the greatest attention, vis-à-vis the development of small-molecule antiviral agents.³⁰ Herein, we report the development of an anti-filoviral screening system, based on a pseudotyping strategy, and its application in the discovery of a novel group of small molecules that selectively inhibit the GP-mediated entry of Ebola and Marburg viruses into human cells.

Results and Discussion

1. Chemistry

In order to confirm the chemical identity of lead hit compound **8a** and also to provide sufficient material for more detailed evaluation of its biological activity, our initial undertaking was to develop an efficient solution-phase synthesis of this small molecule. As shown in Scheme 1, **8a** was conveniently prepared through a Huisgen 1,3-dipolar cycloaddition using the one-pot, copper(I)-catalyzed method reported by Fokin.³¹ Thus, *p*-anisaldehyde (**10a**) was first converted to the corresponding aldoxime **11**³² via reaction with hydroxylamine in the presence of aqueous sodium hydroxide. Without isolation, this substrate was treated with chloramine-T trihydrate³³ to generate the corresponding nitrile oxide **12**, which in the presence of a catalytic amount of copper(I) sulfate and copper powder, underwent [2+3] cycloaddition³⁴ with terminal alkyne **13**³⁵ at ambient temperature, to furnish 3,5-disubstituted isoxazole **8a** in good overall yield. Notably, this reaction proceeded with excellent regioselectivity, as evidenced by analysis of the unpurified reaction product mixture by ¹H NMR studies, which indicated the absence of the regioisomeric cycloadduct.

Employing the three step, one-pot sequence detailed in Scheme 1, a library of C-5 substituted analogs of compound **8a**, where prepared from the corresponding aryl and aliphatic aldehydes and alkyne **13**. In all cases, only a single isoxazole regioisomer was isolated from the reaction mixture (Table 1). In order to evaluate the impact of changes in both the steric and electronic properties of the arene ring, a variety of substitution patterns were examined as well as heterocyclic analogs, as in the case of **8m**.

In order to examine the role which the core isoxazole ring of **8a** plays in the anti-filoviral activity of this compound, a group of 1,4-disubstituted 1,2,3-triazoles analogs **15** were

synthesized through the 1,3-dipolar cycloaddition of aryl and alkyl azides **14** with terminal alkyne **13** (Table 2). In this case, the copper(I) catalyst was generated in situ by the reduction of copper(II) sulfate with sodium ascorbate, as described by Sharpless.³⁶

In an effort to study the effect of structural variation at and within the 5-(diethylamino)acetamido substituent in **8a**, two sub-groups of derivatives of this system were prepared: those bearing a stereogenic center at the α -position and simple amide derivatives. The first group of derivatives were conveniently accessed through the coupling of **18** (Scheme 2) with a variety of protected amino acid derivatives **19** (Table 3). Common building block **18** in turned was synthesized from cycloadduct **16** through a sequence of *O*-tosylation, substitution with azide and Staudinger reduction.

Unexpectedly, amide coupling of primary amine **18a** (R = OMe) with carboxylic acids **19** proved to be sluggish when mediated by carbodiimide reagents, such as EDC, and lead to incomplete conversion. In an alternative approach to improve the overall efficiency of this transformation, it was found that activation of the amino acid derivatives as their corresponding mixed isobutyl anhydrides and subsequent treatment with **18a** at low temperature ($-40\text{ }^{\circ}\text{C}$), provided the desired amides **20a-g** in good overall yield (Table 3).

While attempts to remove the Cbz protecting group in **20d** and **20f** under hydrogenolytic conditions, in order to gain the corresponding amine for evaluation and coupling with other amino acids or peptides failed, exposure of these compounds to Pd/C under an atmosphere of H_2 did provide a 1:2 mixture of enaminone **21** and 5-methylisoxazole **22** (Scheme 3). Ultimately, access to free amine **20b** was accomplished by treatment of **20a** with TFA.

The second series of aminomethyl derivatives, **20h-n**, incorporated various simple alkyl and aryl chains, including methyl, ethyl, isopropyl, phenyl and bromomethyl groups. All compounds in this group were prepared via the coupling of **18a** or **18b** and the corresponding carboxylic acids to give the desired C-3/C-5 substituted isoxazole products in good to excellent overall yield (Table 4).

Other analogs of lead compound **8a**, including 4,5-dihydroisoxazole **27**, ester derivative **28** and thioamide **29**, were prepared by the dipolar cycloaddition of the nitrile oxide generated from oxime **11** (Scheme 4). The respective dipolarophiles in these reactions, **24**, **25** and **26**, were readily obtained from *N,N*-diethylglycine.

2. Biology

To produce Ebola virus GP pseudotyped HIV virions, 293T cells were co-transfected with the DNA of wild type Ebola Zaire GP (EboZ GP)²⁸ and the vector pNL4-3.Luc.R-E, which contains the *env* deficient HIV proviral genome and an intact firefly luciferase reporter gene (*luc*) inserted into the pNL4-3 *nef* gene.^{37,38} This proviral construct expresses luciferase activity as a marker of viral gene expression and although it carries a deletion within the *env* coding region, contains all sequences necessary for reverse transcription, vector integration, and expression of the reporter gene. Upon transfection of cells, the HIV vector and the plasmid encoding the EboZ virus envelope protein are coated and expressed, generating GP pseudotyped HIV virions. These particles are assembled, released by cell lysis, and harvested. In order to determine the level of incorporation of wt GP protein into the pseudotyped viruses, Western blot analysis of the transfected 293T cell lysates was employed.

To screen for potential Ebola entry inhibitors, individual compounds (30–60 μM , final concentration) were mixed with Ebola GP pseudotyped HIV and the mixture incubated with the target cells (293T). At 24 and 48 hours post-infection, cell morphology was examined

for signs of toxicity using light microscopy. At 48 hours post infection, the cells were lysed and the level of viral infection analyzed by measuring firefly luciferase enzyme activity using a luminometer. DMSO, the vehicle in which test compounds were dissolved, was used as a background control (final concentration of 0.1~0.2%) and found not to significantly effect infection. Compounds initially identified as viral entry inhibitors were retested in order to confirm their antiviral properties. In order to confirm that the hit compounds displayed specificity for the function of the Ebola glycoprotein, VSV-G-pseudotyped HIV virions, which carry the envelope protein of the vesicular stomatitis virus (VSV), were produced and the effect of upon infectivity also examined. Inhibition of Ebola GP-mediated entry, but not VSV-G suggests that inhibition is specifically effecting Ebola GP-mediated entry rather than the pseudotyped core: the only difference between Ebola GP and VSV-G pseudotype viruses is the envelope protein and viral entry. In contrast, inhibition of both Ebola and VSV-G entry likely suggests one of two possible situations: 1) the compound in question inhibits post-entry replication of the HIV vector; 2) the compound is toxic to cells. In order to exclude the possibility of cell line bias, compounds were screened against both 293T and HeLa cells, for which Ebola GP pseudotyped HIV virions exhibit tropism.¹⁷ Select compounds found to specifically inhibit Ebola cell entry were finally evaluated at a range of concentrations in order to determine the dose-dependent inhibition (IC₅₀).

From an initial screen of an “in-house” library of 237 small molecules, two compounds (**8a** and **9** Figure 2) were found to decrease infectivity of the Ebola pseudotype virus without apparent side effects on cell morphology and growth. Consequently, these hit compounds were further evaluated for specificity (Figure 3). In comparison to a DMSO control, compound **8a** blocked Ebola GP entry by over 50% at concentrations of 30 μ M in both 293T and HeLa cells. In contrast, at this concentration **8a** did not affect VSV-G mediated cell entry compared to DMSO. Viral infection without added reagents was also examined as a control (NC), and indicated that there was no differences between NC and DMSO (data not shown). These findings suggest that **8a** specifically blocks Ebola GP-mediated viral entry independent of cell type. Titration showed that the IC₅₀ of **8a** is approximately 30 μ M (Figure 4). Furthermore, **8a** did not affect VSV-G entry even at 120 μ M (data not shown), indicating that the inhibition is specific to Ebola entry and not due to cytotoxicity. In contrast to **8a**, similar analysis of hit compound **9** (data not shown) revealed this oxazolidinone derivative to be a non-selective inhibitor of Ebola-GP, Marburg-GP and VSV-G mediated cell entry. In light of these findings, further studies of this compound were not undertaken.

In order to optimize the anti-viral properties of **8a**, fifty-five derivatives of this lead compound were synthesized and evaluated for inhibition of EBOV-GP-mediated viral-cell entry. The results of this investigation are outlined in Tables 5 (isoxazoles) and Table 6 (triazoles). Most notably, a number of the analogs of **8a** were found to be significantly more potent inhibitors of cell entry, e.g. movement of the methoxy group on the aryl ring from the *para* to *meta* position enhanced the anti-Ebola entry activity (**8b**). Replacement of the methoxy group with halogens, including iodine, bromine, or chlorine, also improved anti-Ebola entry activity (**8k**, **8j**, and **8l**), as did replacement of the *para*-methoxyphenyl group with a 2-furyl substituent (**8m**).

An examination of Table 6 reveals that substitution of the core isoxazole ring in **8a** with a triazole system did not adversely impact anti-viral efficacy. Indeed, a number of triazoles, most notably **15b** and **15k** displayed greater activity than lead compounds **8a**. On the basis of these findings, four of the most active derivatives (**8b**, **8j**, **15b**, and **15k**) were chosen and their IC₅₀ values measured using 293T cells (Figure 5). While the IC₅₀ of **8b** was improved to 10 μ M, compounds **15b** and **15k** displayed higher activity of 5 μ M. The highest anti-

Ebola activity was shown by **8j** ($IC_{50} = 2.5 \mu M$). Notably, none of these four compounds displayed inhibition of VSV-G-mediated cell entry (data not shown).

Replacement of the aryl *p*-methoxy substituent with a more polar hydroxyl group lead to a decrease in anti-viral activity as did removal of the diethylamino group (**20j**), removal of the ethanamide and diethylamino groups (**22**), and replacement of the amide with an ester (**28**).]

Somewhat unexpectedly, a number of compounds, most notably **8q**, the *p*-methyl analog of **8a**, and cysteine derivative **20e** actually enhanced the infectivity of Ebola virus GP pseudotyped HIV virions with 293T cells up to 4 fold. It should be noted, however, that this enhancement of infectivity was found to be cell type-specific, since **8q** and **20e**, did not enhance Ebola GP-mediated entry in HeLa cells (data not shown). Interestingly, only derivative **20n** displayed appreciable toxicity towards cells: at concentrations of 60 μM and above this compound killed 293T cells, which all other compounds evaluated did not show any obvious effects on cell morphology and growth. The pronounced cytotoxicity of **20n** may arise from the presence of the α -bromoamide group, which may act as a biological alkylating agents: notable in this regard is the lack of toxicity displayed by compound **20j**, the debrominated derivative of **20-n**.

Since an earlier study (LR) suggested that Ebola and Marburg viruses might share a common cellular factor for viral entry,²⁸ lead compound **8a** and the three derivatives that displayed improved anti-Ebola activity (**8j**, **15b**, and **15k**) were also evaluated for their ability to inhibit Marburg GP-mediated viral entry (Figure 5). Each compound (final concentration 60 μM) was used to block Marburg entry into 3 different cell lines (293T, HeLa and A549). In comparison to a DMSO control, compound **8a** blocked 20-40% of Marburg entry while **8j**, **15b**, and **15b** displayed more dramatic blocking of Marburg entry, especially in HeLa and A549 (human lung carcinoma) cells (>90%). Therefore, **8a** and three derivatives not only blocked Ebola entry, but also impaired viral entry mediated by Marburg GP independent of cell types. This further supports the hypothesis that Ebola and Marburg viruses share a common cellular factor and a common entry inhibitor could be developed for both viruses.

Conclusions

In summary, we report the development of an anti-filoviral screening system, based on a pseudotyping strategy, and its application in the discovery of a novel group of small molecules that selectively inhibit the Ebola and Marburg glycoprotein (GP)-mediated infection of human cells. Using Ebola Zaire GP-pseudotyped HIV particles bearing a luciferase reporter gene and 293T cells, a library of 237 small molecules was screened for inhibition of GP-mediated viral entry. From this assay, lead compound **8a** was identified as a selective inhibitor of filoviral entry with an IC_{50} of 30 μM . In order to analyze functional group requirements for efficacy, a structure-activity relationship analysis of this 3,5-disubstituted isoxazole was then conducted with 56 isoxazole and triazole derivatives prepared using “click” chemistry. This study revealed that while the isoxazole ring can be replaced by a triazole system, the 5-(diethylamino)acetamido substituent found in **8a** is required for inhibition of viral-cell entry. Variation of the 3-aryl substituent also provided a number of more potent anti-viral agents with IC_{50} values ranging to 2.5 μM . Lead compound **8a** and three of its derivatives were also found to block the Marburg glycoprotein (GP)-mediated infection of human cells. This group of compounds are not only potential leads in the search for therapeutic anti-filoviral candidates, but may also serve as mechanistic probes in the elucidation of the mechanism of filoviral fusion and entry.

Experimental Section

Chemistry

All non-aqueous reactions were carried out in oven- or flame-dried glassware under an atmosphere of nitrogen, unless otherwise noted. All solvents were reagent grade. Triethylamine was distilled from calcium hydride, under nitrogen, and stored over potassium hydroxide. *N,N*-Dimethylformamide (DMF) was purchased from a commercial vendor and dried with freshly activated 4 Å molecular sieves prior to use. All products were purified by flash column chromatography using silica gel 60 (mesh 230-400). All other reagents and starting materials, unless otherwise noted, were purchased from commercial vendors and used without further purification. *N,N*-Diethylglycine and 3-(4-methoxyphenyl)-5-hydroxymethyl isoxazole (**16a**) were prepared according to procedures reported by Tonellato³⁹ and Fokin,³¹ respectively. All melting points were determined in open Pyrex capillaries with a Thomas Hoover Unimelt melting point apparatus and are uncorrected. IR spectra were recorded as thin films on sodium chloride plates or as suspensions in compressed potassium bromide discs. ¹H and ¹³C spectra were recorded on a Bruker Avance 400 (400 MHz ¹H, 100 MHz ¹³C) or a Bruker Avance 500 (500 MHz ¹H, 125 MHz ¹³C) spectrometer. DEPT 135 and two-dimensional (COSY, HMQC, HMBC) NMR experiments were employed, where appropriate, to aid in the assignment of signals in the ¹H NMR spectra. The purity of the compounds was determined using an analytical HPLC (Agilent 1100 with diode-array detector, Supercosil LC 18 (250 mm × 4.6 mm, 5 micron) acetonitrile (unless otherwise noted), 2.00 mL/min) and was confirmed to be ≥95% for all compounds.

General Synthetic Procedure A. Preparation of 3,5-Disubstituted Isoxazoles, as Exemplified by the Preparation of 2-(Diethylamino)-*N*-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)ethanamide (8a**)**—To a solution of *p*-anisaldehyde (140 mg, 1.03 mmol, 1.0 equiv) and hydroxylamine hydrochloride (75 mg, 1.07 mmol, 1.05 equiv) in a mixture of *t*-BuOH and H₂O (1:1, 4 mL) was added 1 M aqueous NaOH (1.1 mL). The reaction mixture was stirred at rt for 4 h, or until thin-layer chromatography indicated consumption of the aldehyde. After oxime formation was complete, chloramine-T (301 mg, 1.07 mmol, 1.05 equiv) was added portionwise over 3 min, followed by CuSO₄·5H₂O (5 mg, 3 mol%) and copper powder (4 mg, 6 mol%). *N*-Propargyl-*N,N*-diethylglycine (**13**) (182 mg, 1.07 mmol, 1.05 equiv) was then added, the pH of the reaction medium adjusted by the addition of 1 M aqueous NaOH (6 drops), and the mixture stirred at rt for 12 h. The reaction was then quenched with 1 M aqueous NH₄OH (1 mL), extracted with EtOAc (3 × 15 mL) and the combined organic extracts dried (Na₂SO₄) and concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel (EtOAc) to provide **8a** (209 mg, 64%): white solid; mp 77-78 °C; *R*_f 0.15 (EtOAc); *t*_R – HPLC: 1.46 min (100 %); FTIR (KBr pellet) ν_{max} 3336 (br), 2967 (br), 1674, 1612, 1514, 1432, 1254, 1177, 1028, 838 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.94 (s, 1 H), 7.71 (d, *J* = 8.7 Hz, 2 H), 6.95 (d, *J* = 8.7 Hz, 2 H), 6.43 (s, 1 H), 4.61 (d, *J* = 6.0 Hz, 2 H), 3.84 (s, 3 H), 3.09 (s, 2 H), 2.56 (q, *J* = 7.1 Hz, 4 H), 1.02 (t, *J* = 7.1 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.5, 169.3, 162.3, 161.1, 128.3 (2 C), 121.5, 114.4 (2 C), 100.0, 57.4, 55.5, 48.9 (2 C), 34.9, 12.4 (2 C); HRMS-EI calcd for C₁₇H₂₄N₃O₃ [M+H]⁺: 318.1812, found: 318.1802.

General Synthetic Procedure B. Preparation of *N,N*-Diethylglycine Derivatives, as Exemplified by the Preparation of *N*-Propargyl-*N,N*-diethylglycine (13**)**—To a stirred solution of *N,N*-diethylglycine (312 mg, 2.4 mmol, 1 equiv) and propargylamine (250 μ L, 3.8 mmol, 1.6 equiv) in anhydrous CH₂Cl₂ (3.7 mL), at rt was added EDC (818 mg, 4.3 mmol, 1.8 equiv) followed by addition of Et₃N (530 μ L, 1.6 equiv). After stirring for 12 h, the reaction was quenched with 1 M aqueous HCl (500 μ L)

and extracted with EtOAc (3 × 10 mL). The combined organic phases were washed with brine (2 × 10 mL), dried (Na₂SO₄), concentrated under reduced pressure, and the residue purified by flash chromatography over silica gel (EtOAc/hexanes, 1:3) to afford **13** (488 mg, 52%): yellow oil; *R*_f 0.25 (EtOAc); IR (film) $\nu_{\max}$ 3308 (br), 2970, 2934, 2823, 1673, 1516, 1456, 1426, 1347, 1260, 1205, 1089 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.53 (br s, 1 H), 4.01 (dd, *J* = 2.4, 5.4 Hz, 2 H), 2.98 (s, 3 H), 2.50 (q, *J* = 7.1 Hz, 4 H), 2.18 (t, *J* = 2.4 Hz, 1 H), 0.98 (t, *J* = 7.1 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.0, 79.8, 71.3, 57.4, 48.9 (2 C), 28.6, 12.4 (2 C); HRMS-EI calcd for C₉H₁₆N₂O [M+H]⁺: 96.1072, found: 96.1074.

General Synthetic Procedure C. Preparation of 3,5-Disubstituted Triazoles, as Exemplified by the Preparation of 2-(Diethylamino)-*N*-(1-(4-methoxyphenyl)-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15a)—

To a solution of 1-azido-4-methoxybenzene (108 mg, 0.72 mmol, 1.0 equiv) in a mixture of *t*-BuOH and H₂O (1:1, 3 mL) was added *N*-propargyl-*N,N*-diethylglycine (**13**) (109 mg, 0.72 mmol, 1.0 equiv), followed by addition of 1M aqueous sodium ascorbate (72 μ L, 0.1 mmol) and CuSO₄·5H₂O (2.5 mg, 0.02 mmol, 6 mol%). The heterogeneous reaction mixture was stirred vigorously at rt for 12 h. After completion of the reaction, as indicated by thin-layer chromatography, it was diluted with water (15 mL) and extracted with EtOAc (3 × 15 mL). The combined organic extracts were dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude 1,2,3-triazole was purified by flash chromatography over silica gel (EtOAc) to provide **15a** (174 mg, 82%): off-white solid; mp 109–110 °C; *R*_f 0.10 (EtOAc); *t*_R – HPLC: 5.4 min (MeOH, 99.6 %); FTIR (KBr pellet) $\nu_{\max}$ 3349 (br), 2966 (br), 1672, 1518, 1255, 1043, 833 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 8.05 (br s, 1 H), 7.89 (s, 1 H), 7.60 (dd, *J* = 1.9, 5.0 Hz, 1 H), 7.00 (dd, *J* = 1.9, 5.0 Hz, 1 H), 4.60 (d, *J* = 6.2 Hz, 2 H), 3.86 (s, 3 H), 3.05 (s, 2 H), 2.53 (q, *J* = 7.2 Hz, 4 H), 0.99 (t, *J* = 7.2 Hz, 6 H); ¹³C NMR (125 MHz, CDCl₃) δ 172.6, 160.0, 145.6, 130.7, 122.3 (2 C), 120.7, 114.9 (2 C), 57.7, 55.8, 48.9 (2 C), 34.59, 12.4 (2 C); HRMS-EI calcd for C₁₆H₂₃N₅O₂ [M+H]⁺: 318.1930, found: 318.1942.

General Synthetic Procedure D. Preparation of 3,5-Disubstituted Isoxazoles via Amide Coupling, as Exemplified by the Preparation of Benzyl 2-((3-(4-methoxyphenyl)isoxazol-5-yl)methylamino)-2-oxoethylcarbamate (20f)—

To a stirred solution of carbobenxyloxyglycine (200 mg, 0.618 mmol, 1 equiv) in anhydrous CH₂Cl₂ (5 mL) under an atmosphere of nitrogen, at –40 °C (MeCN/CO₂), was added isobutyl chloroformate (105 μ L, 0.624 mmol, 1.05 equiv) and triethylamine (86 μ L, 0.618 mmol, 1 equiv). After stirring for 10 min, the cold bath was removed and reaction mixture was allowed to warm to rt and stirred for 12 h. 3-(4-Methoxyphenyl)isoxazol-5-yl)methanamine (**18b**) (100 mg, 0.618 mmol, 1 equiv) and triethylamine (86 μ L, 0.618 mmol, 1 equiv) were then added sequentially. The reaction mixture was stirred for 12 h at rt then quenched with 1M aqueous HCl and the aqueous portion extracted with EtOAc (3 × 20 mL). The combined organic extracts were dried (Na₂SO₄), filtered and concentrated under reduced pressure. The residue was purified by flash chromatography over silica gel (EtOAc/hexanes, 1:4) to provide **20f** (332 mg, 88%): white solid; mp 117–119 °C; *R*_f 0.28 (EtOAc/hexanes, 1:3); *t*_R – HPLC: 1.46 min (100 %); FTIR (KBr pellet) $\nu_{\max}$ 3323, 3285, 1690, 1658, 1548, 1293, 1247, 1165, 1074 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 8.41 (d, *J* = 8.7 Hz, 2 H), 8.03 (m, 5 H), 7.65 (d, *J* = 8.7 Hz, 2 H), 7.27 (s, 1 H), 6.08 (br s, 1 H), 5.96 (s, 2 H), 5.81 (s, 2 H), 4.69 (d, *J* = 5.9 Hz, 2 H), 4.54 (s, 3 H), 2.86 (s, 1 H); ¹³C NMR (100 MHz, CDCl₃) δ 169.7, 166.2, 162.4, 161.3, 156.5, 129.7, 128.7 (2 C), 128.3 (5 C), 121.1, 114.5 (2 C), 102.5, 67.4, 57.2, 55.5, 42.7; HRMS-EI calcd for C₂₁H₂₂N₃O₅ [M+H]⁺: 396.4165, found: 396.4168.

2-(Diethylamino)-*N*-((3-(3-methoxyphenyl)isoxazol-5-yl)methyl)ethanamide

(8b)—Yield 36%: white solid; mp 90–92 °C; R_f 0.10 (EtOAc); t_R – HPLC: 1.47 min (97.6 %); FTIR (KBr pellet) $\nu_{\max}$ 3308 (br), 2966, 2926, 1669, 1608, 1506, 1456, 1254, 1158, 1042, 1000 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.05 (s, 1 H), 7.35 (m, 3 H), 7.00 (m, 1 H), 6.43 (m, 1 H), 6.48 (s, 2 H), 4.64 (d, J = 6.2 Hz, 2 H), 3.86 (s, 3 H), 3.12 (s, 2 H), 2.60 (q, J = 7.1 Hz, 4 H), 1.05 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.3, 169.6, 162.7, 160.1, 130.2, 130.1, 119.5, 116.4, 111.8, 100.5, 57.4, 48.9 (2 C), 35.0, 29.9, 12.3 (2 C); HRMS-ESI calcd for $\text{C}_{17}\text{H}_{24}\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$: 318.38122, found: 318.18129.

2-(Diethylamino)-*N*-((3-(4-hydroxyphenyl)isoxazol-5-yl)methyl)ethanamide (8c)

—Yield 62%: colorless oil; R_f 0.12 (EtOAc); t_R – HPLC: 1.45 min (99.2 %); IR (film) $\nu_{\max}$ 3349 (br), 2967, 2811, 1671, 1517, 1487, 1373, 1203, 1036, 856 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.17 (s, 1 H), 7.56 (d, J = 8.7 Hz, 2 H), 6.87 (d, J = 8.7 Hz, 2 H), 6.31 (s, 1H), 4.59 (d, J = 6.2 Hz, 1 H), 3.12 (s, 2 H), 2.59 (q, J = 7.1 Hz, 4 H), 0.91 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 173.5, 168.8, 162.4, 158.5, 128.5 (2 C), 121.0, 116.2 (2 C), 100.5, 57.4, 49.0 (2 C), 35.1, 12.4 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{21}\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$: 303.3562, found: 303.3568.

2-(Diethylamino)-*N*-((3-(4-nitrophenyl)isoxazol-5-yl)methyl)ethanamide (8d)

Yield 17%: colorless oil; R_f 0.12 (EtOAc); t_R – HPLC: 1.45 min (100 %); IR (film) $\nu_{\max}$ 3338 (br), 2967, 2966, 2853, 1673, 1610, 1522, 1456, 1434, 1229, 1157, 1074, 914, 842 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.32 (d, J = 8.8 Hz, 2H), 8.12 (br s, 1 H), 7.98 (d, J = 8.8 Hz, 2 H), 6.58 (s, 1 H), 4.66 (d, J = 6.3 Hz, 2 H), 3.11 (s, 2 H), 2.58 (q, J = 7.1 Hz, 4 H), 1.04 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.8, 170.9, 161.0, 149.0, 135.2, 127.9 (2C), 124.4 (2 C), 100.6, 57.5, 49.0 (2 C), 34.9, 12.5 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{21}\text{N}_4\text{O}_4$ $[\text{M}+\text{H}]^+$: 333.3623, found: 333.3628.

2-(Diethylamino)-*N*-((3-(3-nitrophenyl)isoxazol-5-yl)methyl)ethanamide (8e)

Yield 15%: off-white solid; mp 90–91 °C; R_f 0.11 (EtOAc); t_R – HPLC: 1.45 min (98.8 %); FTIR (KBr pellet) $\nu_{\max}$ 3291, 3152, 3054, 2967, 2932, 2805, 1654, 1525, 1498, 1348, 1224, 1045, 984 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.62 (m, 1 H), 8.31 (dd, J = 2.1, 8.2 Hz, 1 H), 8.15 (d, J = 7.9 Hz, 1 H), 8.04 (br s, 1H), 7.66 (t, J = 8.0 Hz, 1 H), 6.59 (s, 1 H), 4.67 (d, J = 6.3 Hz, 2 H), 3.12 (s, 2 H), 2.60 (q, J = 7.1 Hz, 4 H), 1.05 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.7, 170.9, 160.9, 148.8, 132.7, 130.9, 130.3, 124.9, 122.04, 100.4, 57.5, 49.00 (2 C), 35.02, 12.5 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{21}\text{N}_4\text{O}_4$ $[\text{M}+\text{H}]^+$: 333.3623, found: 333.3629.

2-(Diethylamino)-*N*-((3-(4-(trifluoromethyl)phenyl)isoxazol-5-yl)methyl)ethanamide (8f)

—Yield 58%: colorless oil; R_f 0.11 (EtOAc); t_R – HPLC: 1.47 min (96.8 %); IR (film) $\nu_{\max}$ 3308, 2967, 2927, 1672, 1608, 1515, 1354, 1252, 1176, 898, 832 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.19 (s, 1 H), 7.91 (d, J = 8.1 Hz, 2 H), 7.72 (d, J = 8.1 Hz, 2 H), 6.55 (s, 1 H), 4.65 (d, J = 6.2 Hz, 2 H), 3.16 (s, 2 H), 2.63 (q, J = 7.2 Hz, 4 H), 1.07 (t, J = 7.2 Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 170.3, 161.6, 132.5, 131.9, 128.7, 127.3 (2 C), 126.1 (2 C), 100.4, 57.3, 48.8 (2 C), 35.0, 29.9, 12.15 (2 C); HRMS-ESI calcd for $\text{C}_{17}\text{H}_{21}\text{F}_3\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$: 356.15804, found: 356.15787.

***N*-(3-(3,4-Dimethoxyphenyl)isoxazol-5-yl)methyl)-2-(diethylamino)ethanamide (8g)**

—Yield 12%: colorless oil; R_f 0.11 (EtOAc); t_R – HPLC: 1.44 min (96.6 %); IR (film) $\nu_{\max}$ 3324 (br), 2965, 2933, 1674, 1605, 1516, 1426, 1262, 1206, 1134, 1074, 809 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.02 (br s, 1 H), 7.39 (d, J = 1.9 Hz, 1 H), 7.27 (d, J = 1.9 Hz, 1 H), 6.92 (s, 1H), 6.91 (s, 1 H), 6.46 (s, 1 H), 5.30 (s, 1 H), 4.61 (d, J = 6.2 Hz, 2 H), 3.91 (s, 3 H), 3.90 (s, 3 H), 3.11 (s, 2 H), 2.58 (q, J = 7.0 Hz, 4 H), 2.17 (s, 2 H), 1.04 (t, J = 7.0 Hz,

6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 169.2, 161.2, 151.6, 150.6, 129.1, 127.4, 119.9, 110.9, 109.2, 107.7, 100.0, 57.2, 56.0, 48.7 (2 C), 34.8, 12.2 (2 C); HRMS-EI calcd for $\text{C}_{18}\text{H}_{26}\text{N}_3\text{O}_4$ $[\text{M}+\text{H}]^+$: 348.4167, found: 348.4162.

2-(Diethylamino)-*N*-((3-phenylisoxazol-5-yl)methyl)ethanamide (8h)—Yield 66%: white solid; mp 118–120 °C; R_f 0.37 (EtOAc); t_R – HPLC: 1.42 min (100 %); FTIR (KBr pellet) ν_{max} 3331 (br), 2965, 2933, 1709, 1612, 1529, 1432, 1366, 1253, 1175, 1029, 837 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.10 (s, 1 H), 7.78 (m, 2 H), 7.45 (m, 3 H), 6.50 (s, 1 H), 4.67 (d, J = 6.2 Hz, 2 H), 3.16 (s, 2 H), 2.63 (q, J = 7.1 Hz, 4 H), 1.07 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 169.6, 162.8, 136.5, 132.2, 130.3, 129.1 (2 C), 127.0 (2 C), 100.4, 57.3, 49.0 (2 C), 35.0, 12.3 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{22}\text{N}_3\text{O}_2$ $[\text{M}+\text{H}]^+$: 288.3648, found: 288.3651.

***N*-((3-(2-methoxyphenyl)isoxazol-5-yl)methyl)-2-(diethylamino)ethanamide (8i)**—Yield 60%: colorless oil; R_f 0.12 (EtOAc); t_R – HPLC: 1.43 min (100 %); IR film ν_{max} 3308 (br), 2962, 2926, 1669, 1603, 1506, 1456, 1254, 1158, 1042 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.97 (br s, 1 H), 7.85 (dd, J = 1.7, 7.7 Hz, 1 H), 7.40 (dt, J = 1.7, 9.0 Hz, 1 H), 7.02 (t, J = 7.5 Hz, 1 H), 7.0 (d, J = 8.4 Hz, 1 H), 4.63 (d, J = 6.1 Hz, 2 H), 3.86 (s, 3 H), 3.09 (s, 2 H), 2.56 (q, J = 7.1 Hz, 4 H), 1.03 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.4, 168.3, 160.3, 157.3, 131.4, 129.5, 121.3, 121.0, 117.9, 111.6, 103.6, 57.4, 49.0 (2 C), 35.0, 12.4 (2 C); HRMS-ESI calcd for $\text{C}_{17}\text{H}_{24}\text{N}_3\text{O}_3$ $[\text{M}+\text{H}]^+$: 318.18122, found: 318.18129.

***N*-((3-(4-iodophenyl)isoxazol-5-yl)methyl)-2-(diethylamino)ethanamide (8j)**—Yield 68%: white solid; mp 104–105 °C; R_f 0.21 (EtOAc); t_R – HPLC: 1.45 min (95.4 %); FTIR (KBr pellet) ν_{max} 3287 (br), 3123, 2968, 2935, 2870, 2819, 1666, 1521, 1425, 1216, 1067, 1027 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.99 (br s, 1H), 7.79 (d, J = 6.5 Hz, 2 H), 7.51 (d, J = 6.5 Hz, 2 H), 6.45 (s, 1 H), 4.63 (d, J = 6.2 Hz, 2 H), 3.08 (s, 2 H), 2.55 (q, J = 7.3 Hz, 4 H), 1.02 (t, J = 7.3 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.6, 170.1, 162.0, 138, 129.5 (2 C), 128.6 (2 C), 100.2, 96.5, 57.5, 49.0 (2 C), 35.0, 12.5 (2 C); HRMS-ESI calcd for $\text{C}_{16}\text{H}_{21}\text{IN}_3\text{O}_2$ $[\text{M}+\text{H}]^+$: 414.06730, found: 414.06654.

***N*-((3-(4-bromophenyl)isoxazol-5-yl)methyl)-2-(diethylamino)ethanamide (8k)**—Yield 64%: yellow oil; R_f 0.11 (EtOAc); t_R – HPLC: 1.47 min (98.2 %); IR (film) ν_{max} 3307 (br), 2966, 2923, 1670, 1508, 1427, 1275, 1072, 830 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.04 (s, 1 H), 7.64 (d, J = 8.4 Hz, 2 H), 7.58 (d, J = 8.4 Hz, 2 H), 6.47 (s, 1 H), 4.63 (d, J = 6.1 Hz, 2 H), 4.29 (s, 2 H), 3.16 (s, 2 H), 2.61 (q, J = 6.9 Hz, 4 H), 0.88 (t, J = 6.9 Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.5, 170.0, 161.8, 136.3, 129.5 (2 C), 128.3 (2 C), 127.6, 100.3, 57.4, 49.0 (2 C), 35.0, 12.5 (2 C); HRMS-ESI calcd for $\text{C}_{16}\text{H}_{21}\text{BrN}_3\text{O}_2$ $[\text{M}+\text{H}]^+$: 366.08117, found 366.08056.

***N*-((3-(4-chlorophenyl)isoxazol-5-yl)methyl)-2-(diethylamino)ethanamide (8l)**—Yield 42%: white solid; mp 81–83 °C; R_f 0.11 (EtOAc); t_R – HPLC: 1.46 min (97.1 %); FTIR (KBr pellet) ν_{max} 3286 (br), 2969, 1659, 1521, 1424, 1090, 1028, 847, 805 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.01 (s, 1 H), (d, J = 8.4 Hz, 2 H), (d, J = 8.4 Hz, 2 H), 6.47 (s, 2 H), 4.63 (d, J = 6.2 Hz, 2 H), 3.10 (s, 2 H), 2.57 (q, J = 7.1 Hz, 4 H), 1.03 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.6, 170.0, 161.8, 136.3, 129.4 (2 C), 128.3 (2 C), 127.6, 100.3, 57.5, 49.0 (2 C), 35.0, 12.5 (2 C); HRMS-ESI calcd for $\text{C}_{16}\text{H}_{21}\text{ClN}_3\text{O}_2$ $[\text{M}+\text{H}]^+$: 322.13168, found: 322.13131.

2-(Diethylamino)-*N*-((3-(2-furyl)isoxazol-5-yl)methyl)ethanamide (8m)—Yield 56%: colorless oil; R_f 0.16 (EtOAc); t_R – HPLC: 1.46 min (96.8 %); IR (film) ν_{max} 3342

(br), 2966 (br), 2928, 1669, 1517, 1455, 1334, 1259, 1207, 1049 (br) cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.08 (br s, 1 H), 7.54 (dd, $J = 0.6, 1.2$ Hz, 1 H), 6.87 (dd, $J = 0.5, 2.8$ Hz, 1 H), 6.51 (dd, $J = 1.6, 1.8$ Hz, 1 H), 6.43 (s, 1 H), 4.61 (d, $J = 6.2$ Hz, 2 H), 3.15 (s, 2 H), 2.62 (d, $J = 7.1$ Hz, 4 H), 1.05 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 169.4, 155.1, 144.1, 111.9, 110.6, 99.9, 57.01, 49.0 (2 C), 34.9, 29.9, 28.8, 12.3 (2 C); HRMS-EI calcd for $\text{C}_{14}\text{H}_{20}\text{N}_3\text{O}_3[\text{M}+\text{H}]^+$: 278.3269, found: 278.3265.

2-(Diethylamino)-*N*-((3-(pentafluorophenyl)isoxazol-5-yl)methyl)ethanamide (8n)—Yield 68%: white solid; mp 100–102 °C; R_f 0.39 (EtOAc); t_R – HPLC: 1.42 min (100 %); FTIR (KBr pellet) ν_{max} 3316, 2973, 2939, 2877, 2823, 1670, 1508, 1423, 1388, 1361, 1211, 1079, 995, 817 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.02 (br s, 1 H), 6.51 (s, 1 H), 4.70 (d, $J = 6.2$ Hz, 2H), 3.11 (s, 2 H), 2.58 (q, $J = 7.0$ Hz, 4 H), 1.04 (t, $J = 7.0$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.4, 170.2, 161.0, 151.7, 145.8, 143.8, 139.0, 137.0, 103.6, 103.1, 57.2, 48.8 (2 C), 34.7, 12.2 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{17}\text{F}_5\text{N}_3\text{O}_3 [\text{M}+\text{H}]^+$: 378.3171, found: 378.3176.

2-(Diethylamino)-*N*-((3-propylisoxazol-5-yl)methyl)ethanamide (8o)—Yield 46%: colorless oil; R_f 0.11 (EtOAc); t_R – HPLC: 1.47 min (100 %); IR (film) ν_{max} 3324 (br), 2965, 2933, 1674, 1605, 1516, 1426, 1262, 1206, 1134, 1074, 809 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.82 (br s, 1 H), 6.00 (s, 1 H), 4.55 (d, $J = 6.2$ Hz, 1 H), 3.10 (s, 2 H), 2.61 (t, $J = 7.5$ Hz, 2 H), 2.57 (q, $J = 7.1$ Hz, 4 H), 1.67 (s, 2 H), 1.03 (t, $J = 7.1$ Hz, 6 H), 0.97 (t, $J = 7.4$ Hz, 3 H), 1.05 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.7, 164.3, 125.5, 101.8, 57.4, 49.0 (2 C), 35.0, 28.2, 21.8, 13.9, 12.4 (2 C); HRMS-EI calcd for $\text{C}_{13}\text{H}_{24}\text{N}_3\text{O}_2 [\text{M}+\text{H}]^+$: 254.3486, found: 254.3489.

2-(Diethylamino)-*N*-((3-(2,6-dimethylphenyl)isoxazol-5-yl)methyl)ethanamide (8p)—Yield 69%: colorless oil; R_f 0.12 (EtOAc); t_R – HPLC: 1.44 min (96.1 %); IR (film) ν_{max} 3319 (br), 2969 (br), 2932, 2871, 2823, 1676, 1601, 1513, 1456, 1423, 1388, 1355, 1207, 1162 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.00 (br s, 1 H), 7.20 (t, $J = 7.9$ Hz, 1 H), 7.08 (d, $J = 7.9$ Hz, 2 H), 6.09 (s, 1 H), 4.66 (d, $J = 6.3$ Hz, 2 H), 3.08 (s, 2 H), 2.54 (q, $J = 7.1$ Hz, 4 H), 2.12 (d, $J = 2.7$ Hz, 6 H), 1.01 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.4, 169.3, 162.3, 137.4 (2 C), 129.2, 128.9 (2 C), 127.6, 103.1 (2 C), 57.4, 49.04 (2 C), 34.9, 20.4, 12.4 (2 C); HRMS-EI calcd for $\text{C}_{18}\text{H}_{26}\text{N}_3\text{O}_2 [\text{M}+\text{H}]^+$: 316.2019, found: 316.2010

2-(Diethylamino)-*N*-((3-(4-methylphenyl)isoxazol-5-yl)methyl)ethanamide (8q)—Yield 50%: yellow oil; R_f 0.17 (EtOAc); t_R – HPLC: 1.43 min (100 %); IR (film) ν_{max} 3330 (br), 2962, 1674, 1612, 1516, 1432, 1254, 1168, 1026 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 8.15 (br s, 1H), 7.66 (d, $J = 7.9$ Hz, 2H), 7.24 (d, $J = 7.9$ Hz, 2H), 6.48 (s, 1H), 4.61 (br s, 1H), 4.11 (q, $J = 7.2$ Hz, 4H), 2.39 (s, 3H), 1.25 (t, $J = 7.2$ Hz, 6H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.3, 169.3, 162.3, 161.3, 137.4 (2 C), 129.2, 128.9 (2 C), 127.6, 102.1, 57.4, 49.04 (2 C), 34.9, 12.4 (2 C); HRMS-EI calcd for $\text{C}_{17}\text{H}_{24}\text{N}_3\text{O}_2 [\text{M}+\text{H}]^+$: 302.3914, found: 302.3926.

***N*-((3-(3-Iodo-4-methoxyphenyl)isoxazol-5-yl)methyl)-2-(diethylamino)ethanamide (8r)**—Yield 62%: colorless oil; R_f 0.22 (EtOAc); t_R – HPLC: 1.43 min (99.6 %); IR film ν_{max} 3324 (br), 2960, 2928, 1668, 1605, 1516, 1426, 1262, 1134, 1071 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.20 (d, $J = 2.1$ Hz, 1 H), 7.99 (s, 1 H), 7.73 (dd, $J = 2.0, 8.4$ Hz, 1 H), 6.86 (d, $J = 8.5$ Hz, 1 H), 6.45 (s, 1 H), 4.61 (d, $J = 6.2$ Hz, 2 H), 3.93 (s, 3 H), 3.11 (s, 2 H), 2.57 (q, $J = 7.1$ Hz, 4 H), 1.03 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.6, 169.7, 161.1, 159.6, 138.0, 128.3, 119.5, 111.0, 100.1,

86.4, 57.5, 56.7, 49.0 (2 C), 35.0, 12.5 (2 C); HRMS-EI calcd for $C_{17}H_{23}IN_3O_3$ $[M+H]^+$: 444.0784, found: 444.0789.

2-(Diethylamino)-*N*-((1-(4-iodophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15b)—Yield 90%: white solid; mp 127–129 °C; R_f 0.19 (MeOH/EtOAc, 1%); t_R – HPLC: 5.3 min (MeOH, 97.2 %); FTIR (KBr pellet) $\nu_{\max}$ 3291, 3152, 3054, 2967, 2932, 2805, 1654, 1525, 1498, 1348, 1224, 1045 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$) δ 8.02 (br s, 1 H), 7.97 (s, 1 H), 7.81 (d, J = 8.7 Hz, 2 H), 7.47 (d, J = 8.7 Hz, 2 H), 4.58 (d, J = 6.1 Hz, 2 H), 3.04 (s, 2 H), 2.52 (q, J = 7.1 Hz, 4 H), 0.96 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 172.6, 146.1, 139.0 (2 C), 136.7, 122.1 (2 C), 120.3, 93.7, 57.5, 48.8 (2 C), 34.5, 12.3 (2 C); HRMS-EI calcd for $C_{15}H_{21}IN_5O$ $[M+H]^+$: 414.2646, found: 414.2648

***N*-((1-(4-Chlorophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)-2-(diethylamino)ethanamide (15c)**—Yield 55%: white solid; mp 100 °C; R_f 0.61 (EtOAc/hexanes, 1:3); t_R – HPLC: 1.47 min (97.6 %); FTIR (KBr pellet) $\nu_{\max}$ 3286 (br), 2972, 1660, 1521, 1424, 1090, 1028 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$) δ 8.02 (br s, 1 H), 7.96 (s, 1 H), 7.66 (d, J = 8.8 Hz, 1 H), 7.49 (d, J = 8.8 Hz, 2 H), 4.59 (d, J = 6.2 Hz, 2 H), 3.04 (s, 1 H), 2.52 (q, J = 7.1 Hz, 4 H), 0.99 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 172.8, 146.2, 135.7, 134.8, 130.1 (2 C), 121.8 (2 C), 120.6, 57.6, 48.9 (2 C), 34.5, 12.4 (2 C); HRMS-EI calcd for $C_{15}H_{21}ClN_5O$ $[M+H]^+$: 322.1435, found: 322.1437.

***N*-((1-(4-Bromophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)-2-(diethylamino)ethanamide (15d)**—Yield 86%: yellow solid; mp 116–118 °C; R_f 0.17 (EtOAc); t_R – HPLC: 1.45 min (100 %); FTIR (KBr pellet) $\nu_{\max}$ 3288 (br), 3056, 2970, 2817, 1663, 1500, 1349, 1265, 1045 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 8.03 (br s, 1 H), 7.97 (s, 1 H), 7.62 (m, 4 H), 4.59 (d, J = 6.1 Hz, 2 H), 3.04 (s, 3 H), 2.52 (q, J = 7.1 Hz, 4 H), 0.98 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 172.7, 146.2, 136.1, 133.1 (2 C), 122.6, 122.0 (2 C), 120.5, 57.6, 48.9 (2 C), 34.5, 12.4 (2 C); HRMS-EI calcd for $C_{15}H_{21}BrN_5O$ $[M+H]^+$: 367.2641, found: 367.2643.

2-(Diethylamino)-*N*-((1-heptyl-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15e)—Yield 59%: white solid; mp 120 °C; R_f 0.10 (EtOAc); t_R – HPLC: 1.47 min (98.8 %); FTIR (KBr pellet) $\nu_{\max}$ 3297, 1646, 1544, 1420, 1264, 1221, 1026 cm^{-1} ; 1H NMR (400 MHz, $CDCl_3$) δ 7.95 (br s, 1 H), 7.51 (s, 1 H), 4.53–4.56 (m, 1 H), 4.31–4.33 (m, 1 H), 3.04 (s, 2 H), 2.55 (q, J = 7.1 Hz, 4 H), 1.88 (m, 2 H), 1.33 (m, 9 H), 0.99 (t, J = 7.1 Hz, 6 H), 0.87 (t, J = 5.1 Hz, 3 H); ^{13}C NMR (100 MHz, $CDCl_3$) δ 172.6, 145.1, 122.1, 57.6, 50.6, 48.9 (2 C), 34.6, 31.8, 29.9, 28.8, 26.6, 22.7, 14.2, 12.5 (2 C); HRMS-EI calcd for $C_{16}H_{32}N_5O$ $[M+H]^+$: 310.2610, found: 310.2604.

2-(Diethylamino)-*N*-((1-phenyl-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15f)—Yield 50%: white solid; mp 92 °C; R_f 0.29 (MeOH/EtOAc, 1%); t_R – HPLC: 1.47 min (99.7 %); FTIR (KBr pellet) $\nu_{\max}$ 3288 (br), 3153, 3056, 2970, 2933, 2871, 2817, 1663, 1524, 1500, 1349, 1265, 1224 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 8.03 (br s, 1 H), 7.97 (s, 1 H), 7.60–7.65 (m, 4 H), 4.59 (d, J = 6.1 Hz, 2 H), 3.04 (s, 2 H), 2.52 (q, J = 7.1 Hz, 4 H), 0.99 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 172.7, 146.2, 136.1, 133.1 (2 C), 122.6, 122.0 (2 C), 120.5, 57.6, 48.9 (2 C), 34.5, 12.5 (2 C); HRMS-ESI calcd for $C_{15}H_{21}BrN_5O$ $[M+H]^+$: 366.09240, found: 366.09183.

***N*-((1-(2-Nitrophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)-2-(diethylamino)ethanamide (15g)**—Yield 42%: yellow oil; R_f 0.13 (MeOH/EtOAc, 1%); t_R – HPLC: 1.46 min (100 %); IR $\nu_{\max}$ 3343, 2970, 2934, 2874, 2821, 1668, 1536, 1355, 1039 cm^{-1} ; 1H NMR (500 MHz, $CDCl_3$) δ 8.05 (dd, J = 1.4, 8.1 Hz, 2 H), 7.85 (s, 1 H), 7.78 (dt, J = 1.4, 7.7 Hz, 1 H), 7.68

(dt, $J = 1.4, 8.1$ Hz, 1 H), 7.59 (dd, $J = 1.4, 8.0$ Hz, 1 H), 4.63 (d, $J = 6.1$ Hz, 1 H), 3.05 (s, 2 H), 2.52 (q, $J = 7.1$ Hz, 4 H), 0.99 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.7, 145.8, 144.6, 134.0, 131.0, 130.3, 127.9, 125.7, 124.0, 57.5, 48.9 (2 C), 34.4, 12.4 (2 C); HRMS-EI calcd for $\text{C}_{15}\text{H}_{21}\text{N}_6\text{O}_3$ $[\text{M}+\text{H}]^+$: 333.1675, found: 333.16758.

***N*-((1-(3-Iodophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)-2-(diethylamino)ethanamide (15h)**—Yield 87%: yellow solid; mp 77 °C; R_f 0.29 (EtOAc); t_R – HPLC: 1.47 min (100 %); FTIR (KBr pellet) ν_{max} 3343, 2967, 2933, 1668, 1587, 1519, 1486, 1043 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.1 (t, $J = 1.7$ Hz, 1 H), 8.03 (br s, 1 H), 7.99 (s, 1 H), 7.75 (d, $J = 8.0$ Hz, 2 H), 7.70 (dd, $J = 1.8, 8.0$ Hz, 1 H), 7.24 (t, $J = 8.0$ Hz, 1 H), 4.60 (d, $J = 6.2$ Hz, 2 H), 3.05 (s, 2 H), 2.53 (q, $J = 7.1$ Hz, 4 H), 0.99 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.7, 146.1, 138.2, 137.9, 131.3, 129.4, 120.6, 119.7, 94.6, 57.6, 48.9 (2 C), 34.5, 12.4 (2 C); HRMS-EI calcd for $\text{C}_{15}\text{H}_{21}\text{N}_5\text{OI}$ $[\text{M}+\text{H}]^+$: 414.0791, found: 414.0788.

2-(Diethylamino)-*N*-((1-(3-methoxyphenyl)-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15i)—Yield 78%: yellow oil; R_f 0.12 (MeOH/EtOAc, 1%); t_R – HPLC: 1.46 min (97.2 %); IR (film) ν_{max} 3346, 2967, 2932, 1670, 1609, 1506, 1254, 1157, 1043 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.03 (br s, 1 H), 7.97 (s, 1 H), 7.41 (t, $J = 8.2$ Hz, 1 H), 7.33 (t, $J = 2.2$ Hz, 1 H), 7.24 (d, $J = 1.4$ Hz, 1 H), 6.97 (dd, $J = 2.7, 8.2$ Hz, 1 H), 4.62 (d, $J = 6.2$ Hz, 2 H), 3.82 (s, 3 H), 3.06 (d, $J = 4.4$ Hz, 2H), 2.54 (q, $J = 7.1$ Hz, 4 H), 1.02 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.6, 160.8, 145.8, 138.2, 130.7, 120.5, 114.9, 112.5, 106.4, 57.6, 55.9, 48.9 (2C), 34.5, 12.5 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{24}\text{N}_5\text{O}_2$ $[\text{M}+\text{H}]^+$: 318.3941, found: 318.3943.

***N*-((1-Benzyl-1*H*-1,2,3-triazol-4-yl)methyl)-2-(diethylamino)ethanamide (15j)**—Yield 80%: white solid; mp 67–69 °C; R_f 0.15 (EtOAc); t_R – HPLC: 1.47 min (99.2 %); FTIR (KBr pellet) ν_{max} 3342 (br), 2966 (br), 2928, 1669, 1517, 1455, 1334, 1259, 1207, 1049 (br) cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.85 (br s, 1 H), 7.36 (s, 1 H), 7.27 (m, 2 H), 7.18 (m, 1 H), 5.42 (s, 2 H), 4.43 (d, $J = 6.1$ Hz, 2 H), 2.92 (s, 2 H), 2.41 (q, $J = 7.1$ Hz, 4 H), 0.87 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (125 MHz, CDCl_3) δ 172.4, 145.5, 134.7, 129.2 (2 C), 128.9, 128.2 (2 C), 122.0, 57.5, 48.8 (2C), 34.4, 29.8, 12.3 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{23}\text{N}_5\text{O}$ $[\text{M}+\text{H}]^+$: 302.1981, found: 302.1983.

2-(Diethylamino)-*N*-((1-(2,4,6-tribromophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15k)—Yield 67%: white solid; mp 129–130 °C; R_f 0.22 (EtOAc/hexanes, 1:1); t_R – HPLC: 1.46 min (97.1 %); FTIR (KBr pellet) ν_{max} 3349 (br), 2967, 2811, 1671, 1517, 1487, 1373, 1203, 1036 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.87 (br s, 1 H), 7.87 (s, 1 H), 7.72 (s, 1 H), 7.53 (s, 1 H), 4.67 (d, $J = 1.1$ Hz, 1 H), 3.04 (s, 1 H), 2.52 (q, $J = 7.1$ Hz, 4 H), 0.97 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.6, 145.5, 135.4 (2 C), 132.6, 129.1, 125.6, 123.7, 123.4, 57.6, 49.2 (2C), 34.4, 12.6 (2 C); HRMS-ESI calcd for $\text{C}_{15}\text{H}_{19}\text{Br}_3\text{N}_5\text{O}$ $[\text{M}+\text{H}]^+$: 521.91342, found: 521.91266.

2-(Diethylamino)-*N*-((1-(2,4,6-trichlorophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15l)—Yield 23%: yellow solid; mp 102–103 °C; R_f 0.74 (EtOAc/hexanes, 1:3); t_R – HPLC: 1.46 min (96.0 %); FTIR (KBr pellet) ν_{max} 3349 (br), 2967, 2822, 1671, 1521, 1487, 1392, 1203, 1036 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.04 (br s, 1 H), 7.70 (s, 1 H), 7.53 (s, 2 H), 4.67 (d, $J = 6.2$ Hz, 2 H), 2.99 (s, 2 H), 2.52 (q, $J = 7.1$ Hz, 4 H), 0.99 (t, $J = 7.1$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.7, 145.4 (2 C), 137.5, 134.6 (2 C), 129.1, 124.6, 57.7, 49.2 (2 C), 34.4, 29.9, 12.6 (2 C); HRMS-EI calcd for $\text{C}_{15}\text{H}_{19}\text{Cl}_3\text{N}_5\text{O}$ $[\text{M}+\text{H}]^+$: 390.0655, found: 390.0656.

2-(Diethylamino)-*N*-((1-(4-methoxy-2-nitrophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15m)—Yield 54%: dark red oil; R_f 0.10 (EtOAc); t_R – HPLC: 1.45 min (99.2 %); IR $\nu_{\max}$ 3347, 2967, 2935, 1670, 1540, 1519, 1351, 1284, 1245, 1039 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.03 (br s, 1 H), 7.78 (s, 1 H), 7.56 (d, J = 2.4 Hz, 1 H), 7.46 (d, J = 8.0 Hz, 1 H), 7.25 (m, 1 H), 7.23 (d, J = 2.7 Hz, 1 H), 4.62 (d, J = 6.1 Hz, 2 H), 3.95 (s, 3 H), 3.04 (s, 2 H), 2.53 (q, J = 7.1 Hz, 4 H), 0.99 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.7, 161.0, 145.6, 129.5, 124.4, 123.2, 119.5, 110.8, 57.6, 56.6, 49.0 (2 C), 34.5, 29.9, 12.5 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{23}\text{N}_6\text{O}_4$ $[\text{M}+\text{H}]^+$: 363.1781, found: 363.1783.

***N*-((1-(2-Bromophenyl)-1*H*-1,2,3-triazol-4-yl)methyl)-2-(diethylamino)ethanamide (15n)**—Yield 78%: yellow oil; R_f 0.77 (EtOAc/hexanes, 1:5); t_R – HPLC: 1.46 min (99.5 %); IR $\nu_{\max}$ 3336, 2967, 2931, 2825, 1670, 1519, 1492, 1041 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 8.05 (br s, 1 H), 7.91 (s, 1 H), 7.73 (dd, J = 1.0, 8.1, 1 H), 7.45–7.53 (app dtd, J = 1.8, 7.8, 16.0 Hz, 2 H), 7.38 (dt, J = 1.8, 7.8 Hz, 1 H), 4.65 (d, J = 6.1 Hz, 2 H), 3.1 (s, 2 H), 2.54 (q, J = 7.1 Hz, 4 H), 0.99 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.47, 144.9, 136.7, 134.1, 131.4, 128.6, 128.3, 124.4, 118.7, 57.5, 49.0 (2 C), 34.5, 12.4 (2 C); HRMS-EI calcd for $\text{C}_{15}\text{H}_{21}\text{BrN}_5\text{O}$ $[\text{M}+\text{H}]^+$: 366.0929, found: 366.0934.

2-(Diethylamino)-*N*-((1-(3,4,5-trimethoxyphenyl)-1*H*-1,2,3-triazol-4-yl)methyl)ethanamide (15o)—Yield 32%: white solid; mp 125–127 °C; R_f 0.11 (EtOAc); t_R – HPLC: 1.47 min (98.8 %); FTIR (KBr pellet) $\nu_{\max}$ 2968, 2931, 1682, 1605, 1509, 1473, 1419, 1231, 1128, 1043, 1006 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.84 (br s, 1 H), 7.95 (s, 2 H), 6.92 (s, 1 H), 4.59 (d, J = 6.2 Hz, 2 H), 3.91 (s, 6 H), 3.87 (s, 3 H), 3.05 (s, 2 H), 2.53 (q, J = 7.1 Hz, 4 H), 0.99 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.7, 154.1, 145.8, 138.4, 133.0 (2 C), 120.8, 98.4 (2 C), 61.23, 57.6, 56.6 (2 C), 48.8 (2 C), 34.5, 12.4 (2 C); HRMS-ESI calcd for $\text{C}_{18}\text{H}_{28}\text{N}_5\text{O}_4$ $[\text{M}+\text{H}]^+$: 378.21358, found: 378.21378.

5-(Azidomethyl)-3-(4-methoxyphenyl)isoxazole (17a)—To a solution of 3-(4-methoxyphenyl)isoxazol-5-yl)methanol (**16a**) (728 mg, 3.55 mmol, 1.0 equiv) and *p*-toluenesulfonyl chloride (682 mg, 3.58 mmol, 1.01 equiv) in dry CH_2Cl_2 (9.5 mL) was added Et_3N (0.560 mL, 4.28 mmol, 1.21 equiv) and reaction mixture was stirred at rt for 12 h, until thin-layer chromatography indicated consumption of the alcohol. The reaction was then quenched with brine (15 mL), extracted with CH_2Cl_2 (3 $\times$ 15 mL) and the combined organic extracts dried (Na_2SO_4) and concentrated under reduced pressure to provide the corresponding tosylate ester (96%). A mixture of this material (1.23 g, 3.43 mmol, 1.0 equiv) and NaN_3 (0.42 g, 6.51 mmol, 1.9 equiv) in DMF (14 mL) was then stirred at rt for 3 h, quenched with brine (30 mL) and extracted with EtOAc (3 $\times$ 15 mL). The combined organic layers were washed with brine (2 $\times$ 15 mL), dried (Na_2SO_4) and concentrated under reduced pressure to provide **17a** (829 mg, 65%); a colorless oil; R_f 0.31 (EtOAc/hexanes, 1:3); IR (film) $\nu_{\max}$ 3129, 2103, 1613, 1431, 1253, 1177, 1028, 837 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.76 (d, J = 8.8 Hz, 2 H), 6.99 (d, J = 8.8 Hz, 2 H), 6.56 (s, 1 H), 4.50 (s, 2 H), 3.87 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 167.0, 162.5, 161.4, 128.5 (2 C), 114.6 (2 C), 101.3, 55.6, 45.8; MS-EI calcd for $\text{C}_{11}\text{H}_{11}\text{N}_4\text{O}_2$ $[\text{M}+\text{H}]^+$: 230.2248, found: 231.0882.

1-(3-(4-Methoxyphenyl)isoxazol-5-yl)methaneamine (18a)—To a solution of 5-(Azidomethyl)-3-(4-methoxyphenyl)isoxazole **17a** (160 mg, 0.695 mmol, 1.0 equiv) in dry THF (2 mL) at 0 °C was added PPh_3 (192 mg, 0.730 mmol, 1.1 equiv) portionwise over 5 min. After stirring at rt for 12 h reaction mixture was quenched with H_2O (5 mL) and extracted with Et_2O (3 $\times$ 15 mL). The combined organic layers were washed with brine (2 $\times$

10 mL), dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel (EtOAc) to provide **18a** (158 mg, 77%): white solid; mp 184 °C, *R*_f 0.10 (EtOAc); *t*_R – HPLC: 20.8 min (THF, 97.9 %); IR (film) ν_{max} 3240 (br), 3058, 1591, 1437, 1333, 1265, 1158, 909, 814 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, *J* = 8.8 Hz, 2 H), 6.94 (d, *J* = 8.8 Hz, 2 H), 6.37 (s, 1 H), 3.97 (s, 2 H), 3.82 (s, 3 H); ¹³C NMR (100 MHz, CDCl₃) δ 174.3, 162.1, 161.0, 128.2 (2 C), 121.7, 114.4 (2 C), 98.5, 55.4, 38.5; MS-EI calcd for C₁₁H₁₂N₂O₂ [M+H]⁺: 205.0972, found: 205.0970.

1-(3-(4-Bromophenyl)isoxazol-5-yl)methaneamine (18b)—To a solution of 5-(Azidomethyl)-3-(4-bromophenyl)isoxazole (393 mg, 0.154 mmol, 1.0 equiv) in dry THF (2 mL) at 0 °C was added PPh₃ (125 mg, 0.476 mmol, 1.1 equiv) portionwise over 3 min. After stirring at rt for 12 h reaction mixture was quenched with H₂O (5 mL) and extracted with Et₂O (3 × 15 mL). The combined organic layers were washed with brine (2 × 10 mL), dried (Na₂SO₄), filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography over silica gel (EtOAc) to provide **18b** (218 mg, 86%): a colorless liquid; *R*_f 0.43 (EtOAc/hexanes, 1:1); *t*_R – HPLC: 20.9 min (THF, 20.8 %); IR (film) ν_{max} 3236 (br), 3018, 1601, 1402, 1333, 1265, 1158, 886 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 8.8 Hz, 2 H), 7.53 (d, *J* = 8.8 Hz, 2 H), 6.55 (s, 1 H), 4.92 (br s, 2 H), 4.83 (s, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 172.3, 148.1, 144.3, 129.9 (2 C), 128.2, 126.2 (2 C), 101.1, 57.2; MS-EI calcd for C₁₀H₉BrN₂O₂ [M+H]⁺: 253.1800, found: 253.1809.

tert-Butyl (S)-1-((3-(4-methoxyphenyl)isoxazol-5-yl)methylcarbamoyl)-2-phenylethylcarbamate (20a)—Yield 84%: white solid; mp 146–148 °C; *R*_f 0.51 (EtOAc/hexanes, 1:1); *t*_R – HPLC: 1.44 min (95.6 %); IR (film) ν_{max} 3296 (br), 2923, 1662, 1612, 1529, 1432, 1366, 1253, 1174, 1029 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.71 (d, *J* = 8.8 Hz, 2 H), 7.27 (m, 4 H), 7.17 (m, 2 H), 6.97 (d, *J* = 8.8 Hz, 2 H), 6.45 (s, 1 H), 6.32 (s, 1 H), 4.99 (s, 1 H), 4.52 (d, *J* = 6.0 Hz, 1 H), 3.87 (s, 3 H), 3.10 (m, 2 H), 1.41 (s, 9 H); ¹³C NMR (125 MHz, CDCl₃) δ 171.6, 168.6, 162.3, 161.2, 136.5 (3 C), 129.0 (2 C), 129.1 (2 C), 128.4 (2 C), 127.3, 121.5, 114.5 (2 C), 100.4, 56.1, 55.6, 38.4, 35.4, 28.5 (3 C); HRMS-ESI calcd for C₂₅H₂₉N₃O₅ [M+H]⁺: 474.19997, found: 474.20001.

(S)-2-Amino-N-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)-3-phenylpropaneamide (20b)—To a *tert*-butyl (S)-1-((3-(4-methoxyphenyl)isoxazol-5-yl)methylcarbamoyl)-2-phenylethylcarbamate (**20a**) (53 mg, 0.117 mmol) was added mixture of TFA and H₂O (9:1, 1.5 mL). After 10 min, EtOH (3 mL) was added and reaction was concentrated under reduced pressure to provide **20b** (36 mg, 88%): white solid; [α]_D –26.1 (*c* = 0.52, MeOH); mp 166–170 °C; *R*_f 0.11 (EtOAc); *t*_R – HPLC: 1.46 min (100 %); FTIR (KBr pellet) ν_{max} 2920, 2851, 1583, 1652, 1558, 1456, 1134 cm⁻¹; ¹H NMR (400 MHz, CD₃OD) δ 7.71 (d, *J* = 8.9 Hz, 2 H), 7.26 (m, 5 H), 7.02 (d, *J* = 8.9 Hz, 2H), 6.49 (s, 1 H), 4.58 (d, *J* = 16.0 Hz, 1 H), 4.45 (d, *J* = 16.0 Hz, 1 H), 4.08 (t, *J* = 7.3 Hz, 1 H), 3.84 (s, 3 H), 3.17 (dd, *J* = 7.4, 13.8 Hz, 1 H), 3.08 (dd, *J* = 7.4, 13.8 Hz, H); ¹³C NMR (100 MHz, CDCl₃) δ 170.6, 169.8, 164.5, 163.8, 163.2, 135.6, 130.6 (2 C), 130.2 (2 C), 129.4 (2 C), 129.0, 122.5, 115.6 (2 C), 101.6, 56.0, 38.8, 36.0; HRMS-EI calcd for C₂₀H₂₂N₃O₃ [M+H]⁺: 352.4070, found: 352.4073.

Benzyl (S)-1-((3-(4-methoxyphenyl)isoxazol-5-yl)methylcarbamoyl)-2-methylpropyl carbamate (20c)—Yield: 48% as a colorless oil; *R*_f 0.26 (EtOAc/hexanes, 1:3); *t*_R – HPLC: 1.60 min (99.8 %); IR (film) ν_{max} 3348 (br), 2965, 1722, 1613, 1529, 1432, 1253, 1028, 837 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.73 (d, *J* = 8.8 Hz, 2 H), 7.36 (m, 3 H), 7.32 (m, 2 H), 6.97 (d, *J* = 8.8 Hz, 2 H), 6.58 (s, 1 H), 5.32 (d, *J* = 13.7 Hz, 2 H), 5.24 (d, *J* = 13.7 Hz, 2 H), 5.12 (s, 2 H), 4.37 (m, 1 H), 3.86 (s, 3 H), 2.20 (m, 1 H),

1.56 (s, 1 H), 0.97 (d, $J = 6.85$ Hz, 3 H), 0.88 (d, $J = 6.85$ Hz, 3 H); ^{13}C NMR (125 MHz, CDCl_3) δ 171.7, 166.4, 162.4, 161.3, 156.4, 128.8 (2 C), 128.4 (5 C), 121.2, 114.5 (2 C), 102.4, 67.4, 59.2, 57.1, 55.6, 31.4, 19.2, 17.7; HRMS-ESI calcd for $\text{C}_{24}\text{H}_{28}\text{N}_3\text{O}_5$ $[\text{M}+\text{H}]^+$: 438.4962, found: 438.4960.

(S)-Benzyl 2-((3-(4-methoxyphenyl)isoxazol-5-yl)methylcarbamoyl)pyrrolidine-1-carboxylate (20d)—Yield 55%: colorless oil; $[\alpha]_{\text{D}} -38.1$ ($c = 0.40$, MeOH); R_f 0.13 (EtOAc/hexanes, 1:1); t_{R} – HPLC: 1.60 min (95.9 %); IR (film) ν_{max} 3315 (br), 2953 (br), 1700, 1612, 1529, 1431, 1356, 1253, 1176, 1118, 1028 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.70 (d, $J = 6.9$ Hz, 2 H), 7.34 (m, 5 H), 6.94 (d, $J = 6.9$ Hz, 2 H), 6.44 (s, 1 H), 5.17 (s, 2 H), 4.57 (m, 2 H), 4.40 (m, 1 H), 3.85 (s, 3 H), 3.53 (m, 2 H), 3.46 (m, 1 H), 2.19 (s, 1 H), 1.83–1.86 (m, 4 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.0, 169.4, 162.4, 161.2, 156.7, 136.4, 128.8 (2 C), 128.4 (2 C), 128.2 (2 C), 121.7, 114.5 (2 C), 100.2, 67.8, 60.8, 55.6, 47.4, 41.2, 35.7, 28.3, 25.8; HRMS-EI calcd for $\text{C}_{24}\text{H}_{26}\text{N}_3\text{O}_5$ $[\text{M}+\text{H}]^+$: 436.1867, found: 436.1856.

(S)-2-(Acetylamino)-3-mercapto-N-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)propanamide (20e)—Yield 37%: white solid; mp 112 °C; R_f 0.51 (EtOAc/hexanes, 1:1); t_{R} – HPLC: 1.60 min (95.4 %); IR (film) ν_{max} 2922, 1671, 1612, 1528, 1431, 1253, 1177, 1028 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.91 (m, 1 H), 7.73 (d, $J = 8.8$ Hz, 2 H), 6.97 (d, $J = 8.8$ Hz, 2 H), 6.45 (s, 1 H), 6.41 (s, 1 H), 4.68 (s, 2 H), 4.02 (s, 2 H), 3.86 (s, 3 H), 3.84 (s, 3 H), 2.07 (d, $J = 4.9$ Hz, 2 H); ^{13}C NMR (125 MHz, CDCl_3) δ 174.3, 170.6, 165.6, 162.3, 161.1, 128.4 (2 C), 121.8, 114.5 (2 C), 100.2, 98.7, 56.2, 55.6, 38.6, 22.7; HRMS-EI calcd for $\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}_5$ $[\text{M}+\text{H}]^+$: 350.1117, found: 350.1108.

tert-Butyl (S)-1-((3-(4-methoxyphenyl)isoxazol-5-yl)methylcarbamoyl)-2-((benzyloxy)carbonyl)ethylcarbamate (20g)—Yield 57%: white solid; $[\alpha]_{\text{D}} -5.0$ ($c = 0.46$, MeOH); mp 86 °C; R_f 0.26 (EtOAc/hexanes, 1:3); t_{R} – HPLC: 1.61 min (97.6 %); IR (film) ν_{max} 3375 (br), 2975, 1717, 1614, 1498, 1253, 1163, 1028 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.71 (d, $J = 8.8$ Hz, 2 H), 7.32 (m, 5 H), 6.95 (d, $J = 8.8$ Hz, 4 H), 6.55 (s, 1 H), 5.55 (d, $J = 8.7$ Hz, 1 H), 5.21 (d, $J = 2.2$ Hz, 2 H), 5.10 (s, 2 H), 4.67 (m, 1 H), 3.84 (s, 3 H), 3.09 (dd, $J = 4.6, 17.2$ Hz, 1 H), 2.90 (dd, $J = 4.6, 17.2$ Hz, 1 H), 1.43 (s, 9 H); ^{13}C NMR (125 MHz, CDCl_3) δ 170.8, 170.6, 166.3, 162.3, 161.2, 155.5, 135.4, 128.7 (5 C), 128.5 (2 C), 114.5 (2 C), 102.3, 80.5, 67.1, 60.5, 57.6, 55.5, 50.1, 36.9, 28.4 (3 C); HRMS-EI calcd for $\text{C}_{27}\text{H}_{31}\text{N}_3\text{O}_7$ $[\text{M}+\text{H}]^+$: 510.5589, found: 510.5598.

Isobutyl((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)carbamate (20h)—To a stirred solution of isobutyl chloroformate (31 μL , 0.183 mmol, 1.01 equiv) in anhydrous CH_2Cl_2 (2 mL) under an atmosphere of N_2 at -40 °C (MeCN/CO_2) and Et_3N (17 μL , 0.182 mmol, 1 equiv) was added 5-aminomethyl-3-(4-methoxyphenyl)isoxazole (**18b**) (159 mg, 0.182 mmol, 1 equiv). After stirring for 10 min the cold bath was removed, reaction mixture was warming up to rt and stirred for 12 h. Reaction was quenched with 1M HCl and the aqueous portion was extracted with EtOAc (3×20 mL). The combined organic extracts were dried (Na_2SO_4) filtered and concentrated under reduced pressure. The residue was purified by flash chromatography over silica gel (EtOAc/hexanes, 1:5) to provide **20h** (52 mg, 93%): colorless oil; R_f 0.42 (EtOAc/hexanes, 1:5); t_{R} – HPLC: 1.61 min (97.2 %); IR (film) ν_{max} 2962, 1751, 1614, 1432, 1253, 1178, 970 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, $J = 8.8$ Hz, 2 H), 6.96 (d, $J = 8.8$ Hz, 2 H), 6.62 (s, 1 H), 5.26 (s, 2 H), 3.97 (d, $J = 6.6$ Hz, 2 H), 3.86 (s, 3 H), 2.17 (s, 2 H), 1.99 (m, 1 H), 1.59 (s, 6 H), 0.95 (d, $J = 6.9$ Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.3, 161.3, 154.8, 129.8, 128.5 (2 C), 121.1, 114.6 (2 C), 102.4, 75.0, 59.7, 55.6, 28.0, 19.1 (2 C); HRMS-EI calcd for $\text{C}_{16}\text{H}_{21}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 305.3489, found: 305.3493.

2-Bromo-*N*-((3-(4-methoxyphenyl)isoxazol-5-yl)methyl)ethaneamide (20i)—

Yield 36%: colorless oil; R_f 0.20 (EtOAc/hexanes, 1:5); t_R – HPLC: 1.62 min (99.2 %); IR (film) $\nu_{\max}$ 2961, 1760, 1614, 1431, 1257, 1023, 802 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, J = 8.6 Hz, 2 H), 6.97 (d, J = 8.6 Hz, 2 H), 6.61 (s, 1 H), 5.31 (s, 2 H), 4.15 (s, 2 H), 3.86 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 166.9, 165.9, 162.4, 161.3, 128.4 (2 C), 121.1, 114.5 (2 C), 102.8, 57.8, 55.5, 40.7; HRMS-EI calcd for $\text{C}_{13}\text{H}_{14}\text{BrN}_2\text{O}_3$ $[\text{M}+\text{H}]^+$: 326.1659, found: 326.1661.

***N*-((3-(4-Bromophenyl)isoxazol-5-yl)methyl)ethanamide (20j)—**Yield: 88% as a white solid; mp 168-169 °C, R_f 0.41 (EtOAc); t_R – HPLC: 1.61 min (98.5 %); FTIR (KBr pellet) $\nu_{\max}$ 3271, 1651, 1558, 1423, 1295, 1224, 1101, 1028, 825 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.5 Hz, 2 H), 7.58 (d, J = 8.5 Hz, 2 H), 7.27 (s, 1 H), 6.50 (br s, 1 H), 4.60 (d, J = 6.0 Hz, 2 H), 2.07 (s, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 170.3, 169.8, 162.0, 132.4 (2 C), 128.5 (2 C), 127.9, 124.7, 100.6, 34.5, 23.3; MS-EI calcd for $\text{C}_{12}\text{H}_{10}\text{Br}_2\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 375.0359, found: 375.0364.

***N*-((3-(4-Bromophenyl)isoxazol-5-yl)methyl)propanamide (20k)—**Yield: 86% as a white solid; mp 171-172 °C, R_f 0.19 (EtOAc); t_R – HPLC: 1.60 min (98.9 %); FTIR (KBr pellet) $\nu_{\max}$ 3207, 1657, 1524, 1360, 828, 725 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.64 (d, J = 8.5 Hz, 2 H), 7.57 (d, J = 8.5 Hz, 2 H), 6.48 (s, 1 H), 6.17 (br s, 1 H), 4.59 (d, J = 5.9 Hz, 2 H), 2.28 (q, J = 7.1 Hz, 2 H), 1.84 (t, J = 7.1 Hz, 3 H); ^{13}C NMR (100 MHz, CDCl_3) δ 174.0, 169.9, 161.9, 132.4, 128.5, 127.9, 124.6, 100.5, 35.3, 29.6, 9.8; MS-EI calcd for $\text{C}_{13}\text{H}_{13}\text{BrN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 310.1665, found: 310.1658.

***N*-((3-(4-Bromophenyl)isoxazol-5-yl)methyl)-2-methylpropanamide (20l)—**Yield 86%: yellow oil; R_f 0.43 (EtOAc/hexanes, 1:1); t_R – HPLC: 1.46 min (99.2 %); IR (film) $\nu_{\max}$ 3287, 1648, 1548, 1424, 1222, 826 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.65 (d, J = 8.5 Hz, 2 H), 7.59 (d, J = 8.5 Hz, 2 H), 6.48 (s, 1 H), 6.48 (br s, 1 H), 4.60 (d, J = 6.0 Hz, 2 H), 2.43 (m, 1 H), 2.19 (d, J = 6.9 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 177.2, 170.0, 161.7, 132.4 (2 C), 128.5 (2 C), 127.9, 124.6, 100.5, 35.7, 35.4, 19.7 (2 C); HRMS-EI calcd for $\text{C}_{14}\text{H}_{15}\text{BrN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 323.1851, found: 323.1895.

***N*-3-(4-Bromophenyl)isoxazol-5-yl)benzamide (20m)—**Yield 90%: white solid; mp 166-168 °C; R_f 0.51 (EtOAc/hexanes, 1:1); t_R – HPLC: 1.60 min (95.6 %); FTIR (KBr pellet) $\nu_{\max}$ 3357, 3262, 1644, 1532, 1306, 1159, 816 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.81 (m, 3 H), 7.65 (m, 2 H), 7.58 (m, 2 H), 7.50 (d, J = 8.2 Hz, 2 H), 7.46 (m, 2 H), 7.31 (d, J = 8.2 Hz, 2 H), 6.77 (br s, 1 H), 6.57 (s, 1 H), 4.82 (d, J = 6.0, 2 H), 2.44 (s, 2 H); ^{13}C NMR (100 MHz, CDCl_3) δ 177.2, 170.0, 161.7, 132.4 (5H), 128.8 (2C), 128.5 (2C), 127.9, 124.6, 100.5, 57.7, 35.4; HRMS-EI calcd for $\text{C}_{17}\text{H}_{14}\text{BrN}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 358.2093, found: 358.2090.

2-Bromo-*N*-((3-(4-bromophenyl)isoxazol-5-yl)methyl)ethanamide (20n)—Yield 73%: yellow oil; R_f 0.11 (EtOAc/hexanes, 1:5); t_R – HPLC: 1.52 min (100 %); IR (film) $\nu_{\max}$ 3296 (br), 1647, 1544, 1420, 1263, 1221, 1027 cm^{-1} ; ^1H NMR (500 MHz, CDCl_3) δ 7.65 (d, J = 8.5 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.13 (br s, 1H), 6.53 (s, 1H), 4.67 (d, J = 6.1 Hz, 2H), 4.13 (s, 2H); ^{13}C NMR (125 MHz, CDCl_3) δ 168.8, 132.4 (2 C), 128.5 (2 C), 127.8, 100.9, 42.6, 35.7; HRMS-EI calcd for $\text{C}_{12}\text{H}_{11}\text{Br}_2\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 372.9187, found: 372.9190.

(3*Z*)-4-Amino-4-(4-methoxyphenyl)but-3-en-2-one (21) and 3-(4-Methoxyphenyl)-5-methylisoxazole (22)—A round-bottom flask was flashed with N_2 and charged with benzyl 2-((3-(4-methoxyphenyl)isoxazol-5-yl)methylamino)-2-

oxoethylcarbamate (**20f**) (21 mg, 0.055 mmol), 5% Pd/C (4 mg, 0.03 mmol) and EtOAc (2.0 mL) then flushed with N₂ and placed under an atmosphere of H₂ (1 atm). After stirring for 3 h at rt, the flask was flushed with N₂ and the reaction mixture filtered through a plug of Celite 521. After thoroughly washing the filter cake with MeOH (25 mL), the combined filtrates were concentrated under reduced pressure and the residue purified by flash chromatography over silica gel (EtOAc/hexanes, 1:1) to afford a mixture of (3*Z*)-4-amino-4-(4-methoxyphenyl)but-3-en-2-one (**21**) (2.2 mg, 21 %) and 3-(4-methoxyphenyl)-5-methylisoxazole (**22**) (4.8 mg, 48 %). Analytical data for **21**: white solid; mp 81-83 °C (lit⁴⁰ 81-84 °C), *R*_f 0.66 (EtOAc); *t*_R – HPLC: 1.48 min (100 %); ¹H NMR (400 MHz, CDCl₃) δ 7.51 (d, *J* = 6.8 Hz, 2 H), 6.94 (d, *J* = 6.8 Hz, 2 H), 5.43 (s, 1 H), 3.85 (s, 3 H), 2.15 (s, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 197.4, 161.8, 160.8, 129.4, 127.9 (2 C), 114.5 (2 C), 94.7, 55.6, 30.0. Analytical data for **22**: white solid; mp 92 °C (lit⁴¹ 92-93 °C); *R*_f 0.84 (EtOAc); *t*_R – HPLC: 1.47 min (97.6 %); ¹H NMR (400 MHz, CDCl₃) δ 7.73 (d, *J* = 8.8 Hz, 2 H), 6.97 (d, *J* = 8.8 Hz, 2 H), 6.24 (s, 1 H), 3.86 (s, 3 H), 2.47 (s, 2 H); ¹³C NMR (100 MHz, CDCl₃) δ 169.8, 162.4, 161.1, 128.4 (2 C), 122.1, 114.5 (2 C), 99.7, 55.6, 12.6.

***N*-Allyl-2-(diethylamino)acetamide (24)**—Yield 80% colorless oil; *R*_f 0.34 (EtOAc); IR (film) $\nu_{\max}$ 3353, 2969, 2934, 2874, 2821, 1677, 1515, 1455, 1205, 1163, 1088, 990, 916 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 7.48 (br s, 1 H), 5.80 (m, 1 H), 5.12 (dq, *J* = 1.5, 17 Hz, 3 H), 5.07 (dq, *J* = 1.3, 10.4 Hz, 1 H), 3.85 (m, 2 H), 3.00 (s, 2 H), 2.51 (q, *J* = 7.1 Hz, 4 H), 0.98 (t, *J* = 7.1 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 171.9, 134.5, 115.9, 57.5, 48.8 (2 C), 41.2, 12.4 (2 C); HRMS-EI calcd for C₉H₁₈N₂O [M+H]⁺: 170.1419, found: 170.1415.

Prop-2-yn-1-yl(diethylamino) acetate (25)—Yield 58%: colorless oil; *R*_f 0.23 (EtOAc); IR (film) $\nu_{\max}$ 3291, 2971, 2844, 1750, 1652, 1456, 1386, 1157, 1008 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 4.70 (d, *J* = 2.5 Hz, 2 H), 3.37 (s, 3 H), 2.65 (q, *J* = 7.2 Hz, 4 H), 2.47 (t, *J* = 2.4 Hz, 1 H), 1.05 (t, *J* = 7.2 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 170.8, 75.1, 60.6, 54.0, 51.9, 47.9 (2 C), 14.4 (2 C); HRMS-EI calcd for C₉H₁₆NO₂ [M+H]⁺: 170.2288, found: 170.2292.

2-(Diethylamino)-*N*-prop-2-yn-1-ylethanthioamide (26)—A solution of *N*-propargyl-*N,N*-diethylglycine (**13**) (222 mg, 1.6 mmol, 1.6 equiv) and Lawesson's reagent (320 mg, 1.0 mmol, 1 equiv) in 6.5 ml of anhydrous THF was heated at reflux for 12 h. The resulting reaction mixture was cooled down to rt and concentrated under reduced pressure. Crude product was purified by flash chromatography over silica gel (EtOAc/hexanes, 1:1) give **26** (126 mg, 87%) as yellow oil: *R*_f 0.60 (EtOAc); IR (film) $\nu_{\max}$ 3208, 2960, 2836, 1683, 1595, 1499, 1461, 1293, 1251, 1135, 1027, 925, 831, 733 cm⁻¹; ¹H NMR (400 MHz, CDCl₃) δ 9.60 (br s, 1 H), 4.47 (s, 2 H), 3.50 (s, 3 H), 2.56 (q, *J* = 7.2 Hz, 4 H), 2.31 (t, *J* = 2.6 Hz, 1 H), 1.01 (t, *J* = 7.2 Hz, 6 H); ¹³C NMR (100 MHz, CDCl₃) δ 201.5, 77.9, 72.8, 65.7, 47.8 (2 C), 34.4, 12.6 (2 C); HRMS-EI calcd for C₉H₁₇N₂S [M+H]⁺: 185.3097, found: 185.3096.

2-(Diethylamino)-*N*-(3-(4-methoxyphenyl)4,5-dihydroisoxazol-5-yl)methyl)ethanamide (27)—Yield 75%: colorless oil; *R*_f 0.14 (EtOAc); *t*_R – HPLC: 1.45 min (98.7 %); IR (film) $\nu_{\max}$ 2967, 2927, 1672, 1608, 1515, 1354, 1252, 1176, 898, 832 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.84 (br s, 1 H), 7.57 (d, *J* = 3.2 Hz, 2 H), 7.26 (d, *J* = 3.2 Hz, 2 H), 4.85 (m, 1 H), 3.84 (s, 3 H), 3.60 (m, 2 H), 3.37 (dd, *J* = 10.7, 16.8 Hz, 1 H), 3.10 (dd, *J* = 10.7, 16.8 Hz, 1 H), 3.03 (d, *J* = 17.1 Hz, 1 H), 2.96 (d, *J* = 17.1 Hz, 1 H), 2.97 (q, *J* = 7.2 Hz, 4 H), 0.94 (t, *J* = 7.2 Hz, 6 H); ¹³C NMR (125 MHz, CDCl₃) δ 173.2, 161.3, 156.5, 128.4 (2 C), 122.0, 114.3 (2 C), 79.8, 57.5, 55.6, 49.0 (2 C), 42.0, 37.9, 12.5 (2 C); HRMS-EI calcd for C₁₇H₂₆N₃O₃ [M+H]⁺: 320.1974, found: 320.1976.

(3-(4-Methoxyphenyl)isoxazol-5-yl)methyl(diethylamino) acetate (28)—Yield 79%: colorless oil; R_f 0.44 (EtOAc); t_R – HPLC: 1.46 min (98.2 %); IR (film) $\nu_{\max}$ 3370 (br), 2967, 2934, 1752, 1613, 1529, 1431, 1253, 1177, 1028, 837 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 7.73 (d, J = 8.6 Hz, 2 H), 6.97 (d, J = 8.6 Hz, 2 H), 6.58 (s, 1 H), 5.25 (s, 2 H), 3.86 (s, 3 H), 3.42 (s, 2 H), 2.67 (q, J = 7.2 Hz, 4 H), 1.07 (t, J = 7.2 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 171.9, 166.9, 162.4, 161.3, 129.8, 128.4 (2 C), 114.5 (2 C), 102.4, 99.9, 55.6, 54.1, 47.9 (2 C), 12.4 (2 C); HRMS-EI calcd for $\text{C}_{17}\text{H}_{23}\text{N}_2\text{O}_4$ $[\text{M}+\text{H}]^+$: 319.1658, found: 319.1657.

2-(Diethylamino)-N-((3-(4-methoxyphenyl)isoxazol-5-yl)ethanethioamide (29)—Yield 54%: yellow oil; R_f 0.67 (EtOAc); t_R – HPLC: 1.45 min (97.1 %); IR (film) $\nu_{\max}$ 2918, 2849, 1611, 1528, 1431, 1383, 1254, 1177, 1114, 1028 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3) δ 10.05 (br s, 1 H), 7.73 (d, J = 8.8 Hz, 2 H), 6.97 (d, J = 8.8 Hz, 2 H), 6.55 (s, 1 H), 5.10 (s, 2 H), 3.86 (s, 3 H), 3.60 (s, 2 H), 2.62 (q, J = 7.1 Hz, 4 H), 1.04 (t, J = 7.1 Hz, 6 H); ^{13}C NMR (100 MHz, CDCl_3) δ 172.5, 167.1, 162.5, 161.3, 128.4 (2 C), 121.4, 14.6 (2 C), 101.2, 55.6, 48.8 (2 C), 40.2, 29.9, 12.5 (2 C); HRMS-EI calcd for $\text{C}_{17}\text{H}_{23}\text{N}_3\text{O}_2\text{S}$ $[\text{M}+\text{H}]^+$: 334.4564, found: 334.4568.

Biology

Cell Lines and Antibodies—293T Human embryonic kidney cells were maintained in Dulbecco's modified Eagle's medium (MEM) supplemented with 10% fetal calf serum with penicillin and streptomycin plus 300 g of Geneticin per mL. HeLa cells were maintained in the same medium without Geneticin. A549 Human alveolar adenocarcinoma cells were maintained in Dulbecco's modified Eagle's medium (MEM) supplemented with 10% fetal calf serum. The mouse monoclonal antibody 12B5-1-1, which recognizes the GP1 of Ebola virus Zaire (EBOZ) GP, was kindly provided by Mary K. Hart (U.S. Army Medical Research Institute of Infectious Diseases).⁴² The mouse anti-HIV p24 monoclonal antibody was obtained from the National Institutes of Health AIDS Research and Reference Reagent program.⁴³

Preparation of Pseudotyped Viruses—To produce Ebola virus GP pseudotyped HIV virions, 293T producer cells were co-transfected with HIV vector pNL4-3-Luc-R-E- (National Institutes of Health AIDS Research and Reference Reagent program; catalogue number 3418)^{37,38} and the DNA of wild-type (wt) Ebola virus Zaire glycoprotein (wt Ebola-GP), which was synthesized by multiple rounds of overlapping PCR based on the EBOZ genome sequence (GenBank accession number L11365). In the pseudotyping experiments, 2 μg DNA of wt Ebola-GP and 2 μg of pNL4-3-Luc-R-E were used to transfect 293T cells (90% confluent) in six-well plates by Lipofectamine 2000 according to the protocol of the supplier (Invitrogen). The supernatants containing the pseudotyped viruses were collected twice (at 24 hours and 48 hours posttransfection), combined, clarified from floating cells and cells debris by low-speed centrifugation, and filtered through a 0.45 μm -pore-size filter (Nalgene). Then, 1 mL of supernatant was used to infect cells, and the rest stored at -80°C for future use.

The plasmid vector expressing the GP of Marburg (Lake Victoria strain) was prepared as previously described.⁴⁴ Marburg virus GP (Lake Victoria strain) and VSV-G pseudotyped HIV virions were produced in a similar manner, *i.e.* through co-transfection with pNL4-3-Luc-R-E-, according to previous published procedures.⁴⁴

Western Blotting—To evaluate EBOZ GP expression, the 293T producer cells were lysed in 0.2 mL of Triton X-100 lysis buffer (50 mM Tris-HCl [pH 7.5], 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, and a protease inhibitors cocktail consisting of 10 g of leupeptin

per mL, 5 g of aprotinin per mL, and 2 mM phenylmethylsulfonyl fluoride) at 48 h after cotransfection. The protein samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride membrane. The membrane was first incubated with anti-EBOZ GP1 monoclonal antibody 12B5-1-1 (1:5000 dilution) for 1 h and then probed with peroxidase-conjugated goat anti-mouse antiserum (Pierce) for 1 h. The bands were visualized by the chemiluminescence method according to the protocol of the supplier (Pierce).

Detection of GP Incorporation in Pseudotyped Viruses—To evaluate the incorporation of wt GP protein into the pseudotyped viruses, 2 mL of pseudotyped virus was layered onto a 3-mL cushion of 20% (wt/vol) sucrose in phosphate-buffered saline and centrifuged at 55,000 rpm for 30 min in a Beckman SW41 rotor. The pelleted pseudotyped viruses were lysed in 50 μ L of Triton X-100 lysis buffer, and a 25- μ L sample was subjected to SDS-PAGE. Expression of the EBOZ GP protein was detected by Western blotting as described above. A mouse anti-HIV p24 monoclonal antibody (1:5,000 dilution) was used as the primary antibody to detect the HIV p24 protein.

Assay of Infectivity of Pseudotyped Viruses—Human 293T, A549, or HeLa cells (3×10^5 cells) were seeded in six-well plates one day prior to infection. These targeted cells were incubated with 1 mL of the pseudotyped viruses for 5 h. The cells were then lysed in 200 μ L of cell culture lysis reagent (Promega) at 48 h post-infection. The luciferase activity was measured using a luciferase assay kit (Promega) and an FB12 luminometer (Berthold detection system) according to the supplier's protocol. Each experiment was done in triplicate and repeated at least three times.

Compound Blocking Assay—Pseudotype viruses were incubated with individual compounds at different concentration (for initial screening, concentrations of 30-60 μ M were employed) briefly at room temperature. This mixture was then added to 293T, A549, or HeLa cells which were seeded one day prior to the assay in poly-L-lysine-treated 24-well plates. After overnight incubation, the supernatant was replaced with fresh media. The cells were lysed in 100 μ L of cell culture lysis reagent (Promega) 48 hours post-infection. The luciferase activity was measured using a luciferase assay kit (Promega) and an FB12 luminometer (Berthold detection system), according to the supplier's protocol.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank the National Institutes of Health (RO1 AI059570 and U01 AI077767) for funding and Mary Kay Hart, U.S. Army Medical Research Institute of Infectious Diseases, for providing the monoclonal anti-GP antibodies. pNL4-3-Luc-R-E was obtained from Nathaniel Landau through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.

Abbreviations

EBOV	Ebola virus
EboZ	Ebola Zaire virus
MARV	Marburg virus
VSV	vesicular stomatitis virus

MLV	murine leukemia virus
HIV	human immunodeficiency virus
GP	glycoprotein
IFN-α	interferon alpha
CatB	cathepsin B
CatL	cathepsin L.
env	viral envelope glycoprotein
IC₅₀	half maximal inhibitory concentration
SAH	<i>S</i> -adenosylhomocysteine hydrolase

References

- (1). (a) Sanchez, A.; Geisbert, TW.; Feldmann, H. Filoviridae: Marburg and Ebola viruses. In: Knipe, DM.; Howley, PM.; Griffin, DE.; Lamb, RA.; Martin, MA., editors. Fields Virology. Wolters Kluwer Health/Lippincott Williams & Wilkins; Philadelphia, PA: 2007. p. 1409-1448. (b) Hoenen T, Groseth A, Falzarano D, Feldmann H. Ebola virus: unravelling pathogenesis to combat a deadly disease. Trends Mol. Med. 2006; 12:206–215. [PubMed: 16616875] (c) Ascenzi P, Bocedi A, Heptonstall J, Capobianchi MR, Di C. Antonino, Mastrangelo E, Bolognesi M, Ippolito G. Ebolavirus and marburgvirus: Insight the [*sic*] filoviridae family. Mol. Aspects of Med. 2008; 29:151–185. [PubMed: 18063023]
- (2). Leroy EM, Rouquet P, Formenty P, Souquiere S, Kilbourne A, Froment JM, Bermejo M, Smit S, Karesh W, Swanepoel R, Zaki SR, Rollin PE. Multiple ebola virus transmission events and rapid decline of central African wildlife. Science. 2004; 303:387–390. [PubMed: 14726594]
- (3). (a) Reed DS, Mohamadzadeh M. Status and challenges of filovirus vaccines. Vaccine. 2007; 25:1923–1934. [PubMed: 17241710] (b) Jones SM, Feldmann H, Stroher U, Geisbert JB, Fernando L, Grolla A, Klenk HD, Sullivan NJ, Volchkov VE, Fritz EA, Daddario KM, Hensley LE, Jahrling PB, Geisbert TW. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nature Med. 2005; 11:786–790. [PubMed: 15937495] (c) Kobinger GP, Feldmann H, Zhi Y, Schumacher G, Gao G, Feldmann F, Jones S, Wilson JM. Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virology. 2006; 346:394–401. [PubMed: 16356525]
- (4). Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine. 2007; 25:993–999. [PubMed: 17055127]
- (5). (a) Bray M. Defense against filoviruses used as biological weapons. Antiviral Res. 2003; 57:53–60. [PubMed: 12615303] (b) Burnett JC, Henchal EA, Schmaljohn AL, Bavari S. The evolving field of biodefense: therapeutic developments and diagnostics. Nature Rev. Drug Dis. 2005; 4:281–297.
- (6). (a) Bray M, Paragas J. Experimental therapy of filovirus infections. Antiviral Res. 2002; 54:1–17. [PubMed: 11888653] (b) Hensley LE, Jones SM, Feldmann H, Jahrling PB, Geisbert TW. Ebola and marburg viruses: pathogenesis and development of countermeasures. Curr. Mol. Med. 2005; 5:761–772. [PubMed: 16375711] (c) Stroher U, Feldmann H. Progress towards the treatment of ebola haemorrhagic fever. Expert Opin. Invest. Drugs. 2006; 15:1523–1535.
- (7). Tseng CKH, Marquez VE, Fuller RW, Goldstein BM, Haines DR, McPherson H, Parsons JL, Shannon WM, Arnett G, Hollingshead M, Driscoll JS. Synthesis of 3-deazaneplanocin-A, a powerful inhibitor of *S*-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities. J. Med. Chem. 1989; 32:1442–1446. [PubMed: 2544721]
- (8). Huggins J, Zhang ZX, Bray M. Antiviral drug therapy of filovirus infections: *S*-adenosylhomocysteine hydrolase inhibitors inhibit ebola virus *in vitro* and in a lethal mouse model. J. Infect. Dis. 1999; 179:S240–S247. [PubMed: 9988190]

- (9). Schneller, SW.; Yang, M. *S*-Adenosylhomocysteine hydrolase inhibitors as a source of anti-filovirus agents. In: Torrence, PF., editor. *Antiviral Drug Discovery for Emerging Diseases and Bioterrorism Threats*. Wiley-Interscience; Hoboken, N.J: 2005. p. 139-152.
- (10). Bray M, Raymond JL, Geisbert T, Baker RO. 3-Deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. *Antiviral Res.* 2002; 55:151–159. [PubMed: 12076759]
- (11). Bray, M. Filoviridae. In: Richman, DR.; Whitley, RJ.; Hayden, FG., editors. *Clinical Virology*. ASM Press; Washington, DC: 2002. p. 875-890. Filoviridae
- (12). Pokrovskii AG, Belanov EF, Volkov GN, Pliasunova OA, Tolstikov GA, Hoefer G, Baltina L, Michaelis M, Kondratenko R, Baltina L, Tolstikov GA, Doerr HW, Cinatl J Jr. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Inhibition of marburg virus reproduction by glycyrrhizinic acid and its derivatives. *Dokl. Chem.* 1995; 344:709–711.
- (13). Mayaux JF, Bousseau A, Pauwels R, Huet T, Henin Y, Dereu N, Evers M, Soler F, Poujade C, Declercq E, Lepecq JB. Triterpene derivatives that block entry of human-immunodeficiency-virus type-1 into cells. *Proc. Natl. Acad. Sci. U. S. A.* 1994; 91:3564–3568. [PubMed: 8170948]
- (14). Geisbert TW, Jahrling PB. Differentiation of filoviruses by electron microscopy. *Virus Res.* 1995; 39:129–150. [PubMed: 8837880]
- (15). Yonezawa A, Cavois M, Greene WC. Studies of ebola virus glycoprotein-mediated entry and fusion by using pseudotyped human immunodeficiency virus type 1 virions: involvement of cytoskeletal proteins and enhancement by tumor necrosis factor alpha. *J. Virol.* 2005; 79:918–926. [PubMed: 15613320]
- (16). Bar S, Takada A, Kawaoka Y, Alizon M. Tyro3 family-mediated cell entry of ebola and marburg viruses. *J. Virol.* 2006; 80:2815–2822. [PubMed: 16501090]
- (17). Chan SY, Speck RF, Ma MC, Goldsmith MA. Distinct mechanisms of entry by envelope glycoproteins of marburg and ebola (Zaire) viruses. *J. Virol.* 2000; 74:4933–4937. [PubMed: 10775638]
- (18). Chandran K, Sullivan NJ, Felbor U, Whelan SP, Cunningham JM. Endosomal proteolysis of the ebola virus glycoprotein is necessary for infection. *Science.* 2005; 308:1643–1645. [PubMed: 15831716]
- (19). Schornberg K, Matsuyama S, Kabsch K, Delos S, Bouton A, White J. Role of endosomal cathepsins in entry mediated by the ebola virus glycoprotein. *J. Virol.* 2006; 80:4174–4178. [PubMed: 16571833]
- (20). Hanewinkel H, Glossl J, Kresse H. Biosynthesis of cathepsin B in cultured normal and I-cell fibroblasts. *J. Biol. Chem.* 1987; 262:12351–12355. [PubMed: 3624262]
- (21). Jane-Valbuena J, Breun LA, Schiff LA, Nibert ML. Sites and determinants of early cleavages in the proteolytic processing pathway of reovirus surface protein $\sigma 3$. *J. Virol.* 2002; 76:5184–5197. [PubMed: 11967333]
- (22). Kolokoltsov AA, Saeed MF, Freiberg AN, Holbrook MR, Davey RA. Identification of novel cellular targets for therapeutic intervention against Ebola virus infection by siRNA screening. *Drug Dev. Res.* 2009; 70:255–265. [PubMed: 20930947]
- (23). Sumi M, Kiuchi K, Ishikawa T, Ishii A, Hagiwara M, Nagatsu T, Hidaka H. The newly synthesized selective Ca^{2+} /calmodulin dependent protein kinase II inhibitor KN-93 reduces dopamine contents in PC12h cells. *Biochem. Biophys. Res. Commun.* 1991; 181:968–975. [PubMed: 1662507]
- (24). Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). *J. Biol. Chem.* 1994; 269:5241–5248. [PubMed: 8106507]
- (25). For overviews of pseudotyped viral vectors, see: (a) Ames RS, Lu Q. Viral-mediated gene delivery for cell-based assays in drug discovery. *Expert. Opin. Drug Discovery.* 2009; 4:243–256. (b) Bouard D, Alazard-Dany N, Cosset FL. Viral vectors: From virology to transgene expression. *Br. J. Pharmacol.* 2009; 157:153–165. [PubMed: 18776913]
- (26). Takada A, Robison C, Goto H, Sanchez A, Murti KG, Whitt MA, Kawaoka Y. A system for functional analysis of Ebola virus glycoprotein. *Proc. Natl. Acad. Sci. U. S. A.* 1997; 94:14764–14769. [PubMed: 9405687]

- (27). Wool-Lewis RJ, Bates P. Characterization of Ebola virus entry by using pseudotyped viruses: identification of receptor-deficient cell lines. *J. Virol.* 1998; 72:3155–3160. [PubMed: 9525641]
- (28). Manicassamy B, Wang J, Jiang H, Rong L. Comprehensive analysis of Ebola virus GP1 in viral entry. *J. Virol.* 2005; 79:4793–4805. [PubMed: 15795265]
- (29). For recent examples of this approach, published during the course of our studies, see References 22 and 30.
- (30). The rhodanine derivative LJ001 has been found to target the lipid membrane of a wide range of enveloped viruses, including Ebola, Marburg and Vesicular stomatitis, and comprises their ability to mediate virus-cell fusion: Wolf MC, Freiberg AN, Zhang TH, Akyol-Ataman Z, Grock A, Hong PW, Li JR, Watson NF, Fang AQ, Aguilar HC, Porotto M, Honko AN, Damoiseaux R, Miller JP, Woodson SE, Chantasirivisal S, Fontanes V, Negrete OA, Krogstad P, Dasgupta A, Moscona A, Hensley LE, Whelan SP, Faull KF, Holbrook MR, Jung ME, Lee B. A broad-spectrum antiviral targeting entry of enveloped viruses. *Proc. Natl. Acad. Sci. U. S. A.* 2010; 107:3157–3162. [PubMed: 20133606]
- (31). Hansen TV, Wu P, Fokin VV. One-pot copper(I)-catalyzed synthesis of 3,5-disubstituted isoxazoles. *J. Org. Chem.* 2005; 70:7761–7764. [PubMed: 16149810]
- (32). Quan C, Kurth M. Solid-phase synthesis of 5-isoxazol-4-yl-[1,2,4]oxadiazoles. *J. Org. Chem.* 2004; 69:1470–1474. [PubMed: 14986998]
- (33). Hassner A, Rai K. Synthetic methods. A new method for the generation of nitrile oxides and its application to the synthesis of 2-isoxazolines. *Synthesis.* 1989:57–59.
- (34). Grünanger, P.; Vita-Finzi, P.; Dowling, JE. *Isoxazoles*. Wiley; New York: 1991. p. 183-196.
- (35). Katsura Y, Nishino S, Inoue Y, Sakane K, Matsumoto Y, Morinaga C, Ishikawa H, Takasugi H. Anti-helicobacter pylori agents. 5. 2-(Substituted guanidino)-4-arylthiazoles and aryloxazole analogues. *J. Med. Chem.* 2002; 45:143–150. [PubMed: 11754586]
- (36). Himo F, Lovell T, Hilgraf R, Rostovtsev VV, Noodleman L, Sharpless KB, Fokin VV. Copper(I)-Catalyzed Synthesis of Azoles. DFT Study Predicts Unprecedented Reactivity and Intermediates. *J. Am. Chem. Soc.* 2005; 127:210–216. [PubMed: 15631470]
- (37). He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR. Human-immunodeficiency-virus type-1 viral-protein-r (vpr) arrests cells in the g(2) phase of the cell-cycle by inhibiting p34(cdc2) activity. *J. Virol.* 1995; 69:6705–6711. [PubMed: 7474080]
- (38). Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human-immunodeficiency-virus type-1 in mononuclear phagocytes. *Virology.* 1995; 206:935–944. [PubMed: 7531918]
- (39). Cleij MC, Scrimin P, Tecilla P, Tonellato U. Efficient and highly selective copper(II) transport across a bulk liquid chloroform membrane mediated by lipophilic dipeptides. *J. Org. Chem.* 1997; 62:5592–5599.
- (40). Valduga CJ, Santis DB, Braibante MEF. Reactivity of p-phenyl substituted beta-enamino compounds using K-10/ultrasound. II. Synthesis of isoxazoles and 5-isoxazolones. *J. Heterocycl. Chem.* 1999; 36:505–508.
- (41). Shvekhgeimer GA, Baranski A, Grzegozek M. Reaction of benzonitrile oxides with conjugated nitroalkenes. *Synthesis.* 1976:612–614.
- (42). Wilson JA, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn AL, Hart MK. Epitopes involved in antibody-mediated protection from Ebola virus. *Science.* 2000; 287:1664–1666. [PubMed: 10698744]
- (43). Simon JH, Fouchier RA, Southerling TE, Guerra CB, Grant CK, Malim MH. The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. *J. Virol.* 2000; 71:5259–5267. [PubMed: 9188594]
- (44). Manicassamy B, Wang J, Rumschlag E, Tymen S, Volchkova V, Volchkov V, Rong L. Characterization of Marburg virus glycoprotein in viral entry. *Virology.* 2007; 358:79–88. [PubMed: 16989883]

Figure 1.

Structure of low-molecular weight compounds that display antiviral activity against the Ebola and/or Marburg virus: 3-deazaadenosine (C-c3Ado, **1**); glycyrrhizinic acid (**2**); latrunculin A (**3**); colchicine (**4**); bafilomycin A1 (**5**); CA-074Me (**6**); and tunicamycin (**7**).

Figure 2.

Using an Ebola Zaire glycoprotein (GP)-pseudotyped HIV virus bearing a luciferase (*luc*) reporter gene and Human 293T, a library of 237 small molecules was assayed for antiviral activity based on prevention of Ebola GP-mediated viral entry. The luciferase activities of the infected cells were determined as a measure of GP-mediated viral infection. From this assay, compounds **8a** and **9** were identified as antiviral agents that inhibit viral cell entry in a dose-dependent manner.

Figure 3.

Inhibition of Ebola GP-mediated infection of 293T and HeLa cells. Shown are the effects of lead compound **8a** (final concentration, 30 μ M) on the infectivity of Ebola virus GP (Ebola-GP) and VSV-G pseudotyped HIV virions (VSV-G) with 293T (■) and HeLa (□) cell lines. To determine the level of viral infection, 293T and HeLa cells were challenged with pseudotypes in the presence and absence of test compounds. After 48 h, luciferase expression was assessed using the method described in the Experimental Section. Infectivity is expressed as a percentage of luciferase activity, relative to the DMSO control. Values are reported as mean of data from three to five independent experiments, $\pm$ standard error.

Figure 4. Concentration-response curve for DMSO control (■) and compound **8a** (◆) (range = 3.75–120 μM), which inhibits Ebola GP-mediated viral entry into 293T cells in a dose dependant manner with an IC_{50} of 30 μM . After 48 h, luciferase expression was assessed using the method described in the Experimental Section and is expressed as relative light units (RLU). Values are reported as mean of data from three independent experiments.

Figure 5.

Concentration-response curve for DMSO control (◆) and compounds **8a** (■), **8b** (▲), **8j** (×), **15b** (*) and **15k** (○) (range = 3.75–60 μM), which inhibit Ebola GP-mediated viral entry into 293T cells in a dose dependant manner with respective IC₅₀ values of 30, 10, 2.5, 5 μM (see also Tables 5 and 6). To determine the level of infection, 293T cells were challenged with pseudotypes in the presence and absence of test compounds. After 48 h, luciferase expression was assessed using the method described in the Experimental Section. Infectivity is expressed as a percentage of luciferase activity, relative to the DMSO control. Values are reported as mean of data from three to five independent experiments, ± standard error.

Figure 6.

Inhibition of Marburg GP-mediated infection. Shown are the effects of compounds **8a**, **8j**, **15b** and **15k** (final concentrations, 60 μ M) on the infectivity of Marburg GP pseudotyped HIV virions with 293T (■), HeLa (□), and A549 (▨) cell lines. To determine the level of infection by pseudotype viruses, cells were challenged with pseudotypes in the presence and absence of test compounds. After 48 h, luciferase expression was assessed using the method described in the Experimental Section. Infectivity is expressed as a percentage of luciferase activity, relative to the DMSO control. Values are reported as mean of data from three independent experiments, $\pm$ standard error.

Scheme 1.

One-Pot, Three Step Synthesis of 3,5-Disubstituted Isoxazole **8a**.^a

^a*Reagents and conditions:* (a) $\text{NH}_2\text{OH}\cdot\text{HCl}$, NaOH , $t\text{-BuOH-H}_2\text{O}$ (1:1), rt, 4 h; (b) $\text{TsN}(\text{Cl})\text{Na}\cdot 3\text{H}_2\text{O}$ (chloramine-T), rt, 3 min; (c) **13**, $\text{CuSO}_4\cdot 5\text{H}_2\text{O}$ (3 mol%), Cu powder (6 mol%), NaOH aq. , rt, 12 h.

Scheme 2. Preparation of Building Blocks **18a** and **18b**.^a

^aReagents and conditions: (a) $\text{NH}_2\text{OH}\cdot\text{HCl}$, NaOH, *tert*-BuOH, H_2O , rt; (b) chloramine-T, propargyl alcohol, $\text{CuSO}_4\cdot 5\text{H}_2\text{O}$ (3 mol%), Cu powder (6 mol%), NaOH aq., rt; (c) TsCl, Et_3N , CH_2Cl_2 ; (d) NaN_3 , DMF; (e) PPh_3 , H_2O , THF, $0\text{ }^\circ\text{C} \rightarrow \text{rt}$, 3 h.

Scheme 3.

Attempted Hydrogenolytic Deprotection of Cbz derivatives **20d** and **20f**.^a

^aReagents and conditions: (a) H₂, Pd/C (10 mol%), EtOAc, 3 h, rt.

Scheme 4. Synthesis of C-5 Amidomethyl Analogs of **8a**.^a

^aReagents and conditions: (a) $\text{NH}_2\text{OH}\cdot\text{HCl}$, NaOH , *tert*-BuOH, H_2O , rt, 4 h; (b) chloramine-T, rt, 3 min; (c) **24**, **25** or **26**, $\text{CuSO}_4\cdot 5\text{H}_2\text{O}$ (3 mol%), Cu powder (6 mol%), NaOH aq., rt, 12 h.

Table 1

Preparation of C-5 Substituted Analogs of Lead Compound **8a**

entry	R	product	entry	R	product
1		8a	10		8j
2		8b	11		8k
3		8c	12		8l
4		8d	13		8m
5		8e	14		8n
6		8f	15	<i>n</i> -Pr	8o

Table 2

Preparation of C-1 Substituted, 1,2,3-Triazole Analogs of Compound **8a**

entry	R	product	entry	R	product
1		15a	9		15i
2		15b	10		15j
3		15c	11		15k
4		15d	12		15l

entry	R	product	entry	R	product
5	<i>n</i> -heptyl	15e	13		15m
6		15f	14		15n
7		15g	15		15o
8		15h			

Table 3Preparation of C-5 Amidomethyl Analogs of Isoxazole **8a**

entry	R ¹	R ²	product
1	NHBoc	Bn	20a
2	NH ₂	Bn	20b ^a
3	NHCbz	<i>i</i> -Pr	20c
4	NHCbz		20d
5	NHAc	CH ₂ SH	20e
6	NHCbz	H	20f
7	NHBoc	CH ₂ COOBn	20g

^a obtained via Boc deprotection of **20a** with TFA.

Table 4Synthesis of C-3/C-5 Substituted Isoxazoles Derivatives of **8a**

entry	R ¹	R ²	product
1	MeO	<i>i</i> -BuO	20h ^a
2	MeO	CH ₂ Br	20i
3	Br	Me	20j
4	Br	Et	20k
5	Br	<i>i</i> -Pr	20l
6	Br	Ph	20m
7	Br	CH ₂ Br	20n

^aPrepared by treatment of **8a** with *i*-BuOCOC(=O)Cl

Table 5

Anti-Ebola Activity Data for Lead Compound **8a** and its Isoxazole Analogs as Inhibitors of Ebola GP-Mediated Cell Entry.^a

Compound	Structure	Infectivity ^b	Compound	Structure	Infectivity
8a		56	8q		381
8b		4	8r		4
8c		132	20a		188
8d		30	20b		106
8e		37	20c		220
8f		24	20d		254
8g		160	20e		421
8h		181	20f		148
8i		87	20g		118
8j		6	20h		118
8k		30	20i		121
8l		17	20j		105
8m		77	20k		99

Compound	Structure	Infectivity ^b	Compound	Structure	Infectivity
8n		52	20l		116
8o		102	20m		82
8p		59	20n		Kills cells at 60 μM

^a Ebola virus GP pseudotyped HIV virions were mixed with compounds prior to infecting 293T cells (final concentration of compounds was 60 μM). After 48 h, luciferase expression was assessed using the method described in the Experimental Section.

^b Infectivity is expressed as a percentage of luciferase activity, relative to the DMSO control.

Table 6

Anti-Ebola Activity Data for Lead Compound **8a** and its Triazole Analogs as Inhibitors of Ebola GP-Mediated Cell Entry.^a

Compound	Structure	Infectivity ^b	Compound	Structure	Infectivity
15a		58	15i		90
15b		4	15j		35
15c		105	15k		3
15d		18	15l		33
15e		60	15m		92
15f		46	15n		19
15g		66	15o		19
15h		111			

^a Ebola virus GP pseudotyped HIV virions were mixed with compounds prior to infecting 293T cells (final concentration of compounds was 60 μM). After 48 h, luciferase expression was assessed using the method described in the Experimental Section.

^b Infectivity is expressed as a percentage of luciferase activity, relative to the DMSO control.